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It has been established that various combinations of three or more antiretroviral 
drugs will lead to durable inhibition of HIV replication in patients. Despite its success in 
controlling the infection, highly active antiretroviral therapy (HAART) does not eradicate 
the virus; systemic infection re-emerges upon treatment interruption in all but exceptional 
cases, necessitating a lifetime of expensive drug therapy with an ever-present risk of 
emerging drug resistance.  
  Using standard colorimetric and fluorometric live/dead cell labeling methods, we 
have developed a novel “selective cell death” assay, and identified a lead drug 
combination for elimination of infected cells, involving a patented combination of 2 
generic FDA approved drugs or their metabolites: the glucocorticoid dexamethasone 
(Dex) and N,N-diethylaminoethanolamine (DEAE, a metabolite of procaine). Neither 
drug alone, but only the combination, is effective in cell killing, and only in HIV-
infected cells (P<0.0001). Furthermore, prolonged exposure of cells to this drug 
combination leads to a decline in viral load; two weeks of treatment results in a 
decrease of more than 50% relative to untreated control cells. Flow cytometric methods 
indicate that the mechanism of infected cell death is via apoptosis. In addition, 
microray analysis has highlighted several host genes whose expression is altered by 
Dex/DEAE treatment, providing initial clues to understanding the pathways leading to 
apoptosis in infected cells. 
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CHAPTER I 
INTRODUCTION: HIV AND AIDS EPIDEMIC 
 In the early 1980s, public health officials began using the term Acquired Immune 
Deficiency Syndrome (AIDS) to refer to a new syndrome characterized by a progressive 
deterioration of the immune system due to a loss of the CD4+ helper/inducer subset of T 
lymphocytes. This loss leads to a severe destruction of the immune functions, and the 
appearance of multiple opportunistic infections in the form of constitutional diseases, 
opportunistic infections, neurological complications (AIDS dementia complex), and 
neoplasms that rarely happen in persons with undamaged immune functions [1]. This 
disease state was caused by human immunodeficiency virus HIV, a lentivirus subfamily 
of retroviruses that produces chronic infection in the host and gradually damages the 
host’s immune system [2]. Three major strains of immunodeficiency-associated 
lentiviruses have been characterized in primates: simian immunodeficiency virus (SIV) 
and among humans, HIV-1, the predominant type in the world, and HIV-2, mostly 
located in Western Africa and India[1]. 
 Nearly thirty years after the discovery of HIV/AIDS, the number of people infected 
in the world has grown rapidly turning the disease into a very complex epidemic, and one 
of the biggest health crises facing the world today.  
 Estimating HIV’s prevsalence is notoriously complicated, frustrated by the 
challenge of acquiring sound statistical data from struggling clinics in developing 
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countries [3]. Keeping these difficulties in mind, recent estimates suggest there were 33.3 
million [31.4 million–35.3 million] people living with HIV at the end of 2009 [4].  
Levels of infection vary greatly across and within many regions of the globe. 
 Significant research has been directed at understanding geographical HIV 
transmission, often to aid in the design of rational prevention and treatment strategies.  
With an estimated 15 million HIV-positive people living in low- and middle-income 
countries today, well tailored means of effective transmission reduction and AIDS 
treatment are vital [5, 6]. 
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Table 1: Regional HIV and AIDS statistics, 2001 and 2009[4] 
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Globally, the epidemic was thought to have peaked in 1999 with 3.1 million [2.9 
million–3.4 million]. Since then the number of new infections has been steadily declining 
and reaching an estimated 2.6 million [2.3 million–2.8 million] people annually in 2009, 
representing approximately one fifth (19%) fall from the peak [4].  
 
 
Figure 1: Number of people newly infected annually with HIV[4] 
 The epidemic disproportionately affects sub-Saharan Africa (SSA) a region that 
comprises 22 of the 33 countries most afflicted with AIDS. Despite an overall reduction 
in transmission rate of 25%, the number of people living with HIV keeps escalating, 
reaching 22.5 million [20.9 million–24.2 million] in 2009[4].  
In these sub- Saharan countries, an estimated 1.8 million [1.6 million–2.0 million] 
people became infected in 2009; a significant improvement from 2.2 million [1.9 
million–2.4 million] in 2001 [4]. These changes are the results of a combination of 
factors, from the impact of colossal HIV prevention efforts and the natural course of HIV 
epidemics. 
Unfortunately not all regions and countries follow this positive overall trend. 
Seven countries saw an increase in HIV incidence of greater than 25% between 2001 and 
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2009. In other regions, such as Central Asia, North America, and Europe, the rates of new 
HIV infections have remained constant for the past five years [4].  
 
 
Figure 2: Changes in the incidence rate of HIV infection, 2001 to 2009, selected 
countries)[4] 
 
 
Global HIV infection rates have declined by an impressive 19% during the last 
decade due to dedicated efforts to endorse and sustain HIV prevention methods that 
support behavioral changes among young people, such as increased condom use, delayed 
sexual debut, and reductions in multiple partnerships [4]. These traditional preventative 
methods are combined with new tools to expand and reinforce effective HIV prevention, 
such as: 
 Prevention of mother to child transmission among women living with HIV in 
countries with high infection rates.  
 Male circumcision: clinical trials demonstrate that male circumcision significantly 
decreases the probability of uninfected men catching HIV from an HIV-infected 
female sex partner. UNAIDS and WHO have both suggested insistent promotion 
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of male circumcision in areas of high HIV prevalence, where rates of 
circumcision have been historically low. 
  Microbicides: the Centre for the AIDS Programme of Research in South Africa 
(CAPRISA) has announced promising results of a tenofovir-based gel for a new 
female-initiated prevention option that reduces HIV infection by 39% and herpes 
simplex virus-2 infection by 51%. The gel also passed safety tests when used once 
within the 12 hours before sex and once in the 12 hours after sex by women aged 
18–40 years [4]. 
Although results of the preventative methods have been very promising, investments 
in HIV prevention programs are still insufficient. The trajectory of the epidemic cannot 
be reversed without augmented investment in additional prevention programs. 
Along with advances in preventive therapy and advances in treatment, 
improvements in care and support services were also a considerable achievement in 2009. 
Among the estimated 15 million people living with HIV in low and middle income 
countries, 36% (about 5.2 million) had access to anti retroviral therapy. While this 
represents greater regional diversity than at any previous time during the epidemic 
period, universal access goals remain unachieved [4]. More efforts need to be done to 
cover the remaining two thirds of people who need HIV treatments but don’t have access 
to them yet, and financing this expansion in access to antiretroviral therapy will require a 
continuous and prolonged global commitment to providing high quality HIV care for all. 
  
 
8 
 
Basic Virology of HIV 
A thorough understanding of the biology of the virus allows a systematic 
development of therapeutic strategies targeted to the inhibition of virus proliferation. An 
understanding of the structure of HIV facilitates understanding of their high rate of 
mutation and the selectivity in their mode of infection and multiplication. 
HIV-1 and HIV-2 are two distinct viruses with many similarities; their genomes 
are a mere 9.8 kilobases, coding for not more than a dozen proteins. The core and matrix 
of viral proteins are enclosed by a lipid envelope, that the virus particle derives from the 
host cell as it is detached from it. It also serves as a means of camouflage for the virus 
from the immune system, as it contains host cellular proteins such as HLA. The envelope 
also contains viral envelope glycoproteins, which are essential for infectivity and 
immunogenicity. 
One of the main differences between the two strains (HIV-1 and HIV-2) is the 
fact that HIV-2 is about 55% different at the sequence levels from HIV-1 and is 
serologically distinct, mostly due to differences in the envelope glycoproteins [7]. 
Usually all retroviruses encode the genes gag, pol and env; in addition to those 
genes, lentivirus genomes encode a number of accessory and regulatory genes. HIV-1 
encodes two regulatory proteins, Tat and Rev, and four accessory proteins [viral 
infectivity factor (Vif), viral protein R (Vpr), viral protein U (Vpu) and so-called negative 
factor (Nef)]. These regulatory proteins are necessary for virus replication as they control 
HIV gene expression in host cells. In contrast, accessory proteins are often dispensable 
for virus replication in vitro [8]. 
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Figure 3: Virion structure: Schematic of the mature HIV-1 virion. The packaging of two 
copies of the viral RNA genome in each particle allows for viral recombination to occur 
during each replicative cycle [9]. 
 
 
 
 
               
Figure 4: Genomic organization of HIV-1, shown as a map of the ~9.8 kb HIV-1 
genome. A total of nine viral genes are encoded (gag, pol, vif, vpr, tat, rev, vpu, env, and 
nef). Gag, pol, and env are the defining features of the retroviral family, encoding capsid 
structural proteins, replicative enzymes, and surface glycoproteins, respectively [7]. 
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Therapeutic Approaches to HIV  
To date, more than 20 antiretroviral drugs have been approved for clinical use. 
These antiretrovirals fall into distinct mechanistic classes, which have been developed for 
their ability to reduce viral replication to clinically undetectable levels. When used in 
appropriate combinations, they can prevent the occurrence of AIDS-related symptoms, 
extending survival and improving the quality of life for HIV infected individuals. [10] 
It has now been established that several different combinations of three or more 
antiretroviral drugs will lead to durable inhibition of HIV replication [11]. This approach 
for the treatment of HIV infection has become known as highly active antiretroviral 
therapy (HAART). The simultaneous use of multiple drugs is required due to the fact that 
HIV-1 can easily develop drug resistance to any single inhibitor.  
Despite its success, HAART does not eradicate the virus; systemic infection re-
emerges upon treatment interruption in all but exceptional cases [12]. Therefore, due to 
its virostatic nature, HAART can control but not cure HIV infection, necessitating a 
lifetime of expensive drug therapy to suppress viral replication, with an ever-present risk 
of emerging drug resistance. 
Currently, five classes (as summarized in table 1) of antiretroviral drugs have 
received FDA approval: nucleoside/nucleotide analog reverse transcriptase inhibitors 
(NRTIs), nonnucleoside analog reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), fusion inhibitors and Integrase Inhibitors [13]. 
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Table 2: Anti HIV FDA approved drugs 
 
Antiretroviral drug 
class 
First 
approved 
to treat 
HIV 
Mechanism of action 
Current 
Antiretrovirals 
Approved by the 
FDA 
Nucleoside/Nucleotide 
Reverse Transcriptase 
Inhibitors (NRTIs, 
nukes) 
1987 
NRTIs are analogs of (RNA, DNA) 
that instead of the hydroxyl in the 3′ 
position have another group that is 
unable to form the 5′ to 3′ 
phosphodiester linkage essential for 
DNA elongation. Therefore 
interfering with reverse transcriptase 
activity by competing with the natural 
substrates and incorporating into viral 
DNA to act as chain terminators in the 
synthesis of proviral DNA. 
Zidovudine(ZDV)/ 
azidothymidine (AZT) 
Didanosine (ddI) 
Stavudine (d4T) 
Lamivudine (3TC) 
Abacavir (ABC) 
Tenofovir (TDF) 
Emtricitabine (FTC 
Non-Nucleoside Reverse 
Transcriptase 
Inhibitors(NNRTIs, 
non-nukes) 
1997 
NNRTIs bind to a site on the reverse 
transcriptase enzyme that is distinct 
from the substrate (dNTP) binding 
site and block DNA polymerase 
activity by causing a conformational 
change and disrupting the catalytic 
site of the enzyme. 
Nevirapine (NVP) 
Delavirdine (DLV) 
Efavirenz (EFV) 
Protease Inhibitors (PIs) 1995 
PIs inhibit the protease enzyme 
responsible for the cleavage of the 
Saquinavir (SQV) 
Indinavir (IDV) 
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large viral precursor polypeptide 
chains into smaller, functional 
proteins, allowing maturation of the 
HIV virion. 
Consequently, inhibition of Protease 
results in the release of structurally 
disorganized 
and noninfectious viral particles. 
Ritonavir (RTV) 
Nelfinavir (NFV) 
Lopinavir/r (LPV/r) 
Atazanavir (ATV) 
Fosamprenavir 
(fAPV) 
Tipranavir (TPV) 
Darunavir (DRV) 
Fusion or Entry 
Inhibitors 
2003 
Enfurvitide is a linear peptide 
homologous to a segment of the HR2 
region of gp41. It binds to the HR1 
region of gp41 and blocks the 
formation of the 6-helix bundle 
necessary for fusion. 
Maraviroc blocks the chemokine 
receptor CCR5 that HIV uses as a 
coreceptor to bind and enter a target 
cell.  Thus both drugs prevent HIV 
from binding to or entering human 
immune cells. 
Enfurvitide (T-20) 
Maraviroc (Celsentri) 
Integrase Inhibitors 2007 
Integrase inhibitors interfere with the 
integrase enzyme that HIV needs to 
insert its genetic material within the 
nucleus of the T-cell. 
Raltegravir 
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The development of drug resistance remains a central problem in the treatment of 
HIV, even with the use of combination chemotherapy (HAART) consisting of at least 
three different drugs.  Because the HIV polymerase (reverse transcriptase) does not have 
operational proofreading mechanisms during replication of its genome, mutations at the 
protein level are common.  Alterations in the proteins targeted by antiretrovirals can 
render the drugs ineffective against mutant viral progeny.  Emerging resistance is often 
addressed therapeutically by utilizing at least three different drugs for HAART, attacking 
a vital viral protein at multiple sites, or targeting several proteins simultaneously. 
As more people develop resistance to PIs and NRTIs/NNRTIs, the development 
of new treatment modalities has become critical. The anti-HIV drug discovery process, 
however, remains focused on screening small molecule, non-vaccine agents that are 
mainly targeted against viral proteins such as HIV protease and reverse transcriptase.   
New Treatment Modalities 
One aspect of possible HIV therapy could be the elimination of infected cells to 
get rid of the virus by eliminating its host cell. This is a viable strategy in the case of HIV 
infection, because only a small percentage of potentially infectable T cells or 
macrophages are actually infected at any given time. The potential drug for such use 
should come from a very specific cytotoxic component.  
This concept is entitled “selective toxicity” that was introduced in the early 
1900’s by Paul Ehrlich, and  has been a cornerstone of chemotherapeutics, and has 
proven very successful in antibacterial treatment as well as in cancer chemotherapy [14], 
while it has been a neglected approach in antiviral research, mainly because for decades 
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virologists were taught that selective toxicity for viruses was unattainable due to their 
status as obligate intracellular parasites. This generalization does not exclude HIV [15]. 
The concept of selective toxicity was among strategies that have at least been considered, 
except that the research that attempted to utilize this concept vs. HIV has involved 
macromolecules, which are not very useful as drugs. However, the “selective toxicity” 
approach vs. HIV does not appear to have been significantly explored for the discovery 
of small drug-like molecules. 
 
 
 
 
15 
 
CHAPTER II 
 INNOVATION AND DRUGS USED 
Innovation 
The proposed research is innovative as it tackles the problem from a different 
perspective that appears to be crucial to complementing the current HIV treatment 
approach as it introduces a new multidrug regimen targeted toward the properties of 
infected cells rather than those of the virus. This class of drugs has the ability to 
selectively eliminate infected cells from the body, it is indeed sometimes spoken of 
almost as a “holy grail” of HIV research [12, 16] but this area still remains undeveloped, 
with little systematic research if any, particularly on the industrial side.  
A part of the reason why this area is so unexplored is due to the fact that in 
traditional pharmaceutical research, the question of toxicity usually only enters into 
consideration as a basis for undesirable side effects, and is evaluated via a series of 
screenings (cellular assays, animal toxicology and Phase I trials). Thus, the existing anti-
HIV drug development pipeline is inherently unlikely to identify a potential treatment 
that might have little or no ability to suppress HIV by inhibiting a known “drug target”, 
yet still be preferentially toxic to infected cells. Such a compound would likely fail the 
first anti-HIV activity screens, and never even get to the phase of toxicity testing. 
Furthermore, the drug discovery process focuses almost exclusively on single molecules, 
16 
 
whereas it is most likely that a combination of two or more small “drug-like” molecules 
would be required to effectively and selectively kill an infected cell. 
The handful of documented attempts to utilize the concept of “selective toxicity” 
vs. HIV have involved high-tech engineered macromolecules, e.g., targeting HIV 
infected cells by conjugating a toxin to the gp120 binding region of human CD4 [17], as 
well as a few targeted gene-therapy based approaches (e.g. involving “cytotoxic 
nucleases” [18]).  But what is needed for a commercially viable HIV treatment using this 
approach, especially for the developing world, is one involving small drug-like 
molecules, either alone or in combination.   
Given this situation, it would not be surprising if a treatment working by this 
mechanism was developed serendipitously, or by some other rationale, or empirical 
observation of efficacy. That may apply to the case of interest here, which is a 
combination of the anti-inflammatory glucocorticoid dexamethasone (Dex) and the local 
anesthetic procaine, developed by Dr. Ruben Fabunan as a patented treatment for several 
types of viral infections, including HIV, dengue virus and influenza virus. The 
mechanism of action of this combination has been poorly understood, although it seemed 
probable that it could involve the procaine metabolite diethylaminoethanol (DEAE), 
which is formed very rapidly and quantitatively from procaine in human blood by the 
hydrolysis of procaine by serum esterases [19]. An early hypothesis that DEAE might 
have virucidal activity targeting the virion itself has been ruled out by earlier studies, as 
well as studies reported below because, given alone, DEAE lacks any significant activity 
against HIV in our assays. 
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The primary hypothesis of this dissertation is that Dex and DEAE achieve their 
apparent anti-HIV effect in humans via the mechanism of selective toxicity vs. HIV-
infected cells, relative to uninfected cells. To validate this hypothesis we develop a novel 
drug discovery “platform technology” for identification of compounds (or mixtures of 
compounds) having the ability to selectively eliminate HIV-infected cells. Various 
studies designed to elucidate the mechanism by which this effect is achieved will also be 
described. 
Drugs Used and Drug Dilutions 
In our assays we have been using a combination of the two drugs dexamethasone 
sodium phosphate and procaine hydrochloride, as described by Dr. Ruben G. Fabunan 
[20]: 
• Dexamethasone sodium phosphate is a water soluble, inorganic ester of 
dexamethasone.is 9-fluoro-11β 17-dihydroxy-16α-methyl-21-(phosphonooxy) pregna-1, 
4-diene-3, 20-dione disodium salt. Its empirical formula is C22H28FNa2O8P and its 
structural formula is: 
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Figure 5: Dexamethasone sodium phosphate formula. 
 
Dexamethasone is a corticosteroid hormone (glucocorticoid) that is a synthetic analog of 
naturally occurring glucocorticoids (hydrocortisone and cortisone). It is used to treat 
various conditions such as severe allergic reactions, arthritis, blood diseases, breathing 
problems, eye diseases, intestinal disorders, and skin diseases. It decreases the body's 
natural defensive response and reduces symptoms such as swelling and allergic-type 
reactions, to relieve inflammation. Dexamethasone is also used to treat certain types of 
cancer. 
• Procaine is a synthetic organic compound used as an anesthetic agent indicated 
for production of local or regional anesthesia, particularly for oral surgery. Procaine (like 
cocaine) has the advantage of constricting blood vessels which reduces bleeding; 
chemically procaine is the PABA (p-amino-benzoic acid) ester of the amino acid alcohol 
DEAE (N,N diethylaminoethanol)[21]. 
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Procaine is metabolized in the plasma at a very high rate by the enzyme 
pseudocholinesterase through hydrolysis into PABA and DEAE. 
 
O
OH
NH2
OH
N
NH2
O
N
O
para-aminobenzoic acid
diethylaminoethanol
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Pseudocholinesterase
+
    
Figure 6: Hydrolysis of Procaine by Pseudocholinesterase 
 
In regard to the hydrolysis of procaine to generate DEAE and PABA, it must be 
noted that cell culture medium is not the same as human blood. Although medium is 
supplemented with 10% fetal bovine serum, which presumably has some ability to 
hydrolyze procaine, this would be significantly slower than in actual blood. Thus we have 
conducted many of our studies using a Dex:DEAE combination to mimic the effect of 
human serum[19].  Previous studies on PABA by our lab failed to detect any anti-HIV 
activity.  We are thus currently focused on DEAE as the likely contributor to selective 
toxicity. 
The Fabunan patent describes a preparation in which 1 volume of dexamethasone 
sodium phosphate (4mg/ml) is mixed with 9 volumes of 2% procaine hydrochloride for 
direct injection into patients [20]. This mixture gives a final molar ratio of 1:69 for 
Dex:Pro, reflecting the much higher potency of Dex.  Based on typical blood levels of 
Dex that are used clinically, and an estimate of what the Fabunan injection might achieve 
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in human blood, we have chosen a 0.1uM concentration of Dex as a “standard 
concentration” for many of the studies described below, e.g. in the selective toxicity 
assays. We have also found this concentration of Dex, as well as the corresponding 6.9 
uM concentration of procaine or DEAE, to be below the threshold of toxicity in our 
uninfected cell lines.  
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CHAPTER III 
HIV SELECTIVE TOXICITY (SELTOX) ASSAY 
Materials and Methods 
We have developed a simple and practical combination of cell-based assays that 
can demonstrate the activity of compounds or mixtures functioning via the mechanism of 
selective killing of HIV-infected cells. This assay is fairly simple in concept. We have 
used a Jurkat T-cell line (Human T cell lymphoblast-like cell line). The protocol is briefly 
as follows:  
• Culture cells on microplates;   
• Infect half of the cells with HIV-1, leave half uninfected; incubate for 4 hours.  
• Expose both groups of cells to various treatments (no drug, drug A or B, etc., 
combination of drugs A and B).   
• After 48 hours incubation, a standard cell viability assay (e.g, MTT or XTT assay) 
is performed [22] .   
A “positive” hit is a compound or mixture that has little or no toxicity to uninfected cells, 
but has a significantly greater toxicity to the HIV-infected cells (fewer viable cells after 
treatment). To assess drug toxicity to infected cells, we compare drug-treated cells to 
infected cells with no drugs, because HIV infection itself can lead to a decline in cell 
numbers, particularly at high viral titers, that is the reason why we have avoided using 
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very high viral titers in the initial infections of cells, because the cytotoxic effects of HIV 
alone at higher MOI (“multiplicity of infection”, the ratio of infectious virions to cells)  
are well known, which reduces the number of viable cells that are available to detect the 
drug effect. So we have generally used a moderate dose of virus (MOI=0.1), and a fairly 
short incubation time of prior to the addition of drugs. The total time frame for the assay 
conducted in a microplate format is limited to three days, after which exhaustion of the 
media and growth capacity of the cells in a 300uL volume might confound the results. In 
order to give the drugs as much time as possible to act, we have reduced the incubation 
time with the virus to 12 hours.  
Due to these factors (low MOI and short incubation time), it is very unlikely that 
all the cells in culture are infected after 12 hours, so even with highly effective killing of 
infected cells, we do not expect to see zero viable cells in these cultures at the end of the 
experiment. This must be kept in mind in interpreting the results.  
Results 
Figures 7-10 show various SelTox assay results, demonstrating that the 
synergistic action of Dex and DEAE can significantly reduce the number of viable cells 
in HIV-infected cell cultures. For this purpose, we have employed two measures of cell 
viability, the MTT assay (Figures 7and 8), and the XTT assay (Figure 9); both yielded 
similar results. Figure 6 combines the data from seven completely independent 
experiments on the Dex-DEAE combination done over a six month period. Note the 
comment in the legend to Figure 8. 
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Figure 7: At the standard concentration based upon 0.1 uM Dex, neither drug, alone or in 
combination, shows significant toxicity in uninfected T cells. Results are from a single 
experiment conducted in sextuplicate, using the MTT assay for cell viability. Drugs were 
incubated with the cells for 48 hrs prior to the MTT assay. Error bars in this and 
subsequent figures represent the S.E.M.; an asterisk is used to indicate a significant 
difference between means. 
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Figure 8:  At the standard concentrations, neither drug alone shows significant toxicity to 
HIV-infected T cells. However, in combination, the drugs produce significant killing of 
infected cells (P<0.005 compared to control). Results are from a single experiment 
conducted in sextuplicate, using the MTT assay for cell viability. Note: Because of the 
low viral titer used (MOI=0.1) and the preincubation time with virus is short (12hrs), not 
all cells in HIV+ cultures are infected; thus, 100% cell death is not expected, since the 
drug combination has no effect on viability of  uninfected cells (as shown in Figure 7). 
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Figure 9: Essentially identical results are obtained using an alternate cell viability assay 
(XTT) with the SelTox assay protocol. The results shown are from a single experiment 
with a 12 hr. pre-incubation with virus prior to addition of drugs.  The asterisk indicates 
that in this experiment the Dex + DEAE combo yielded significantly greater cell death in 
HIV+ cells than in HIV- cells (*, P<0.05), and gave an overall ~40% reduction in cell 
viability in infected cells, compared to untreated HIV+ control cells (P<0.05). 
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Figure 10:  Summary of selective toxicity of the Dex+DEAE combination in Jurkat T 
cells.  The results shown are the average of 7 independent experiments, 3 of which were 
performed using the XTT assay for cell viability, and 4 using the comparable MTT assay, 
from which results were not significantly different (Figures 2-4 above). After 48 hr 
incubation with drugs post-infection, the drug combination at the “standard 
concentration” based on 0.1 uM Dex did not show any toxicity to uninfected cells, but in 
cells preincubated with HIV (at MOI = ~0.1) for 4 to 12 hours, there was significantly 
more cell killing than in cells treated with drugs alone (p<0.0005) or with virus alone 
(p<0.01). A trend showing the ability of HIV alone to reduce the number of viable cells is 
observable, although not statistically significant at the viral titer used here. 
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CHAPTER IV 
INHIBITION OF HIV REPLICATION 
Materials and Methods 
To assess the inhibition of virus replication, we used an antiviral drug assay 
system that has been routinely used in industry for anti-HIV drug discovery. This system 
uses the HeLa-CD4/CCR5 (JC53) cell line, which has been engineered to express 
relatively high surface levels of both the HIV receptor CD4 and  co-receptor CCR5, 
enhancing the susceptibility of the cells to infection [23]. More specifically, we have used 
a variant of JC53 called TZM-bl which, when infected by HIV, are engineered to express 
the gene for the enzyme luciferase [24]. Luciferase serves as a reporter whose activity 
can be quantified using a luminometer; the activity so measured is directly proportional 
to the amount of virus to which the cells are exposed. Thus, this assay system can also be 
used for comparative measurements of viral titer, which can be regarded as proportional 
to viral load (see Figure 11). The potency of antiviral agents can be assessed by their 
ability to inhibit the production of luciferase.
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Results 
Active compounds showing selective toxicity to HIV-infected cells should lead to 
reduced virus production, due to the elimination of infected cells. We have used several 
protocols to verify that the level of infectious virus is actually decreasing in cell cultures 
in which selective killing of HIV-infected cells appears to be taking place. For this 
purpose we have used a “pseudo viral load” assay, which uses the TZM-bl cell line 
described above, one of the applications of which is to measure viral titers. 
 
Figure 11: Standard curve for pseudo viral load assay in TZM-bl (JC53) cells. This 
shows that HIV Tat/LTR-driven luciferase activity in this assay responds linearly to an 
increasing dose of viral stock solution. This assay is used to confirm that treatments that 
appear to selectively kill HIV+ cells actually lead to a reduction in viral load. Inhibition 
of virus replication in these cells is also the basis of the “conventional” antiviral assays. 
Inhibitors of HIV replication lead to reduced luciferase activity. 
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Pro/Dex Combination to Inhibit Viral Replication in TZM-bl Cells 
The procaine and dexamethasone (Pro/Dex) drug combination was found to have 
modest ability to inhibit HIV replication in the TZM-bl cell line, but only at low viral 
titers. For these experiments we used two different viral doses to infect the cultures (MOI 
= 0.1 and MOI = 0.01). Using the Pro/Dex drug combination at the standard 
concentration, we were able to achieve much greater inhibition with the lower viral titer, 
when expressed as a percentage of the total viral replication.  Figure 8 illustrates the 
dependence of the antiviral activity of Pro/Dex upon the viral titer, where as the antiviral 
activity of AZT is independent of MOI used. 
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Figure 12: Inhibition of HIV replication by Pro/Dex is more effective at low viral titres. 
AZT at 0.02uM shows a similar inhibition, about 40%, at both high and low viral titers.  
At lower titer, MOI = 0.01, the Pro/Dex combination standardized to 0.1uM Dex is about 
twice as effective (80 % inhibition) as at high viral titer; at MOI = 0.1, the Pro/Dex 
combination is only able to inhibit about 40% of viral replication. Note: For Figures 8-10, 
data shown are the average of 2 experiments, so error bars are not shown; however, the 
key results are statistically significant based on the standard deviation of replicates in the 
individual experiments. 
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It is an unusual observation that when viral titer is low, the combination is able to 
completely inhibit HIV replication, yet, at higher viral titers; this activity appears to 
become saturated, so that virus replication is maximally reduced by only about 50%. This 
saturable inhibition of HIV replication may be associated with the previously 
documented ability of Dex to inhibit the transcription factor NF-kB, the primary cellular 
activator of HIV [15]. Because other cellular transcription factors can independently 
activate HIV replication, NF-kB inhibition alone is typically insufficient to completely 
suppress HIV replication. Thus, NF-kB inhibition by Dex may at least partly explain 
these observations, and contribute to the HIV replication ability of the Pro/Dex mixture.   
 Pro/Dex and Dex/DEAE show an additive inhibitory effect with AZT: 
  As shown in Figure 9, both the Pro/Dex and Dex/DEAE combinations provide 
significant enhancement to the antiviral activity of AZT. 
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Figure 13: Enhancement of the anti-HIV activity of AZT when combined with either 
Pro/Dex or Dex/DEAE standardized to 0.1uM Dex.  The standard antiviral assay protocol 
was used beginning with an inoculation of HIV at MOI = 0.1. 
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Pro/Dex Activity Against Resistant Strains 
As shown in Figure 14, the antiviral activity of the Pro/Dex combination is the 
same whether or not the viral strain used is AZT resistant, whereas AZT itself is less 
effective against the drug-resistant virus (4 times less effective). There is no reason to 
expect that the results would be any different with other common drug-resistant viral 
strains. 
 
 
Figure 14: Anti-HIV activity of Pro/Dex versus wild type and AZT resistant strains of 
HIV. Pro/Dex was used at a standard concentration of 0.1uM Dex. The standard antiviral 
assay protocol was used beginning with an inoculation of HIV at MOI=0.01. 
 
 
In order to assess whether the treatment with Dex and either DEAE or procaine 
could actually lead to a reduction in viral load over time, we completed two separate 
experiments. The first used a simple protocol. A set of wells containing HIV(+) cells 
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(exposed to drugs or control) from the selective toxicity protocol was maintained for up 
to one additional week.  Fresh media was added with maintenance of the treatment 
conditions. This showed that Dex + DEAE gave significant reductions in “pseudo” viral 
load (PVL), as assessed in TZM-bl cells (using the method shown in Fig. 13). After one 
week of treatment, during which nothing was removed from the cultures, but only an 
equal volume of fresh media added after three days, supernatants of HIV+ cells treated 
with the Dex/DEAE combination showed a 42% reduction in relative PVL as compared 
to untreated HIV+ cells (P<0.01). 
The second experiment, with Dex and Pro instead of Dex and DEAE, used a 
“serial dilution” approach, in which every two days, each 2mL culture was “split”, with 
1mL of the cell suspension being moved to a new well, and 1mL of fresh media added. 
Thus, at each “split”, half of the spent media was removed and the rest diluted with fresh 
media. Freshly added media always contained the same concentration of treatment, 
meaning either no drugs, or the standard concentration of Pro/Dex. At the end of two 
weeks, supernatants from each treatment were assessed in the TZM-bl PVL assay. 
Supernatants of HIV+ cells treated with the Pro/Dex combination showed a 59% 
reduction in relative PVL as compared to untreated HIV+ cells. In this case, note that 
procaine was used; because of the long duration of the study, it seemed more likely that 
substantial hydrolysis could be achieved.  
However, the viral load decrease was not as much as would be expected from the 
Dex/DEAE result from the one week trial (two weeks with a 42% decrease each week 
would give over a 65% reduction at the end of 2 weeks).  So again, this points to the 
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somewhat greater efficacy of DEAE vs. procaine, particularly in the cell culture media 
with only 10% serum where complete hydrolysis of procaine to DEAE may not be 
achieved.  
Nonetheless, based on these 2 results, a 50% decrease after 2 weeks of treatment 
would be a conservative estimate of the attainable decrease in viral load. If that could be 
extrapolated in actual patients (which is speculation at this point), it would mean that if 
the treatment were sustained for about 4 months (8 two-week periods), viral load could 
potentially be reduced to less than 1% of its initial value (0.5^8 < 0.01). 
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CHAPTER V  
FLUORESCENCE EVIDENCE OF THE CELL VIABILITY 
Materials and Methods 
The purpose of this part of the research was the determination of HIV replication 
in vitro and its inhibition by Dexamethasone and DEAE. For that we developed a method 
for monitoring HIV infection, using two different stable human T-lymphoid cell lines: 
• CEM-GFP that contains an HIV-1 long terminal repeat-driven green fluorescent 
protein (GFP) cDNA in which GFP expression is induced by the HIV-1 Tat 
protein. This cell line was obtained through the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: CEM-GFP from Dr. Jacques 
Corbeil. 
• Rev-CEM which is a CEM-SS derived cell line that had been transduced with an 
HIV-1 Rev and Tat dependent GFP expression vector, thereby allowing GFP 
analysis of infected cells. These cells were obtained through the AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH: Rev-CEM cell 
line from Dr. Yuntao Wu and Dr. Jon Marsh.
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Results 
Figure 15 shows the production of GFP in HIV-1 infected cells. The expression of 
GFP by infected cells reached a maximum 4 days post infection. Note that once this 
protein has accumulated in a cell, it persists for some time, even in dying or dead cells.  
Thus in the “infected cells” panel of Figures 16 and 17, we see equivalent amounts of 
GFP produced in all cultures that were infected (HIV+), even though the Live/Dead cell 
labeling shows varying ratios of dead to live cells, as discussed below. This also reflects 
the fact that the cells were exposed to virus a full 3 days prior to the addition of drugs in 
these experiments, giving time for GFP production.  
 
 
Figure 15:  The expression of GFP through cultured T-cells infected with HIV-1 is 
observed via an engineered cell line that expresses the green fluorescent protein (GFP).  
Over time, the number of infected cells increases, and individual infected cells can be 
identified by this marker. 
 
 
We combined the ability of CEM cells to fluoresce green when infected with HIV 
with a LIVE/DEAD® Cell Viability/Cytotoxicity Assay.  This assay, as the name 
implies, is a fluorescence-based method of assessing cell viability. It provides means for 
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the simultaneous determination of live and dead cells, using two probes that measure 
recognized parameters of cell viability: intracellular esterase activity and outer cellular 
membrane integrity.  
Live cells are distinguished by the presence of ubiquitous intracellular esterase 
activity, which may be detected by the enzymatic conversion of the virtually 
nonfluorescent cell-permeant dye Calcein blue AM (excitation/emission maxima 
~322/435 nm). Upon cleavage of the AM esters by intracellular esterases, this tracer 
becomes relatively polar and is retained by cells for several hours. In addition, its 
fluorescence intensity increases and the spectra shift to longer wavelengths, with 
excitation/emission maxima of ~360/449 nm. Dead cells are labeled by the red 
fluorescent dye Ethidium-1, which selectively enters cells with damaged membranes and 
undergoes a 40-fold enhancement of fluorescence upon binding to nucleic acids, thus 
tagging  dead cells (excitation/emission~495 nm/~635 nm) [25].  
The determination of cell viability depends on these physical and biochemical 
properties of cells. Background fluorescence levels are inherently low with this assay 
because the dyes are virtually non-fluorescent before interacting with cells; nonetheless 
the background fluorescence was subtracted from all the results shown. 
We infected the CEM-GFP and Rev-CEM cells with HIV-1 virions at an input MOI of 
0.01, treated them with a standard concentration of Dex and DEAE, and monitored the 
fluorescence via a Synergy Mx microplate reader (Biotek, Inc.). After allowing the virus 
to replicate in the cell culture media alone for 3 days, the different treatments (various 
drugs or saline as a control) were added.  On the fourth day post infection, we detected a 
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significant increase in dead cell count among the HIV infected cells treated with 
“combo.” This combination of drugs showed no toxicity to the uninfected cells, and 
neither Dex nor DEAE alone is able to induce cell death. 
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Figure 16: CEM-GFP cells read with the microplate reader for the 3 fluorophores:  
 Enhanced Green Fluorescent Protein (EGFP) the level of fluorescence is relative to the level of 
infection with HIV-1 virus. 
 Ethidium-1: its level of fluorescence corresponds to the number of dead cells. 
 Calcein blue AM; its level of fluorescence increases with viability of the cells. 
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Figure 17: Rev-CEM cells read with the microplate reader 
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Figure 18: Ethidium-1 (DEAD dye) labeling in CEM-GFP cell line infected by HIV-1, 4 
days after HIV-1 infection at an input MOI of 0.01. CEM-GFP cells were visualized by 
fluorescence microscopy.  At the left: infected cells with no treatment. Note that even in 
“healthy” cell cultures, it is normal to have a small percentage of dead cells, and HIV 
infection alone does cause a slight increase in cell death under these cell culture 
conditions. At the right: infected cells with the combined Dex/DEAE treatment added 
after 3 days, and maintained for an additional 24 hrs. This illustrates visually the results 
assessed quantitatively in the “Dead cells” panels of Figs. 16 and 17, which show (by 
precise counting of the red fluorescent signal) that after only 24 hrs. Exposure to the 
drugs, there are significantly more dead cells in the Dex/DEAE treated HIV+ cell cultures 
as opposed to untreated HIV+ cells, or cells treated with drugs alone. This again supports 
our working hypothesis that the drug combination is selectively toxic to HIV-infected 
cells. 
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Summary 
The results described above demonstrate that neither Dex or DEAE alone exhibits  
significant toxicity to either infected or uninfected cells (Figures 3-5); only the 
Dex/DEAE combination was active, and only in infected cells (Figures 4-6). Since the 
drugs alone or in combination have no effect on the number of uninfected viable cells, the 
most reasonable and obvious explanation of these results is that HIV-infected cells are 
selectively killed by the drug combination.    
These results support our hypothesis that the combination of DEAE and 
dexamethasone has the ability to selectively kill HIV-infected cells. 
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CHAPTER VI 
 MECHANISM OF CELL DEATH 
There are two major mechanisms of cell death: necrosis, which is a consequence 
of a passive degenerative process, and apoptosis, which is the consequence of an active 
process. The latter, also known as “programmed cell death”, is characterized by 
activation of distinct cellular pathways, e.g. involving caspases and other proteins, along 
with DNA fragmentation and other events. The two phenomena are morphologically 
different from each other; their physiological consequences are also very different. 
Apoptosis is triggered by multiple stimuli, and is regulated by one of two known 
cell death-signalling pathways: the extrinsic and intrinsic pathways. The two pathways 
share similar molecules (especially caspases) and features, but differ in the initiation 
method. The extrinsic pathway is usually initiated by external stimuli that are sensed by 
cell-death receptors on the cell membrane, while in the intrinsic pathway mitochondria 
play the major role by releasing apoptosis triggering molecules [16] Morphological 
changes during apoptosis are distinguished by a loss of plasma membrane asymmetry and 
attachment, condensation of the cytoplasm and nucleus, and internucleosomal cleavage of 
DNA. 
Apoptosis is considered a very common response of cells to drugs in the course of 
therapy, and its quantitative evaluation represents an issue of substantial significance. 
Several studies over the years have proven that flow cytometry is the preferred method 
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for the quantitation of apoptosis, and various established assays have been described to 
identify apoptotic cells by flow cytometric analysis. 
For our research, since there is no unequivocal method to distinguish apoptotic 
from necrotic cells by flow cytometry, we chose two different flow cytometric assays 
where we can discriminate necrotic cells from apoptotic cells in HIV-infected cells 
treated with DEAE/Dex.  
Annexin V FITC 
 Materials and Methods 
We used Annexin V-FITC Apoptosis Detection kit by BD (San Jose, CA) that 
uses Annexin V-FITC conjugates which facilitates rapid fluorimetric detection of 
apoptotic cells. The principle of the assay lies in the fact that phospholipid asymmetry is 
disrupted early in the apoptotic process, during the phase of loss of plasma membrane, 
leading to the exposure of phosphatidylserine (PS) on the outer leaflet of the cytoplasmic 
membrane, thus exposing PS to the external cellular environment. This event is important 
for macrophage recognition of cells undergoing apoptosis.  
Annexin V is a 35-36 kDa anticoagulant protein that preferentially binds 
negatively charged phospholipids in a calcium dependent manner with a high affinity for 
PS, and binds to cells with exposed PS. This Annexin V is conjugated to the FITC 
fluorochrome and retains its high affinity for PS, serving as a sensitive probe for flow 
cytometric analysis of cells undergoing apoptosis. This reaction is reversible, and occurs 
with a Kd of approximately 5 x 10-10 M.  
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The advantage of the FITC Annexin V method over other assays that are based on 
nuclear changes such as DNA fragmentation is that it can identify apoptosis at an earlier 
stage, because of the early externalization of PS. 
FITC Annexin V staining precedes the loss of membrane integrity which 
accompanies the latest stages of cell death resulting from either apoptotic or necrotic 
processes.  For that reason,  we used  FITC Annexin V in conjunction with propidium 
iodide (PI), which is excluded by intact membranes in viable cells, while it enters the 
damaged cells and has a specificity for double-stranded nucleic  acids, absorbing in blue-
green (493 nm) and fluorescing red. Then, the flow cytometry results will read as 
follows: 
 Early apoptotic cells (PI negative, FITC Annexin V positive);  
 Viable cells (FITC Annexin V and PI negative); 
 Early apoptotic cells (FITC Annexin V positive and PI negative); 
 Late apoptotic cells (FITC Annexin V and PI positive).  
In order to gate the results of the flow cytometer appropriately, it is important to use 
adequate controls to set up compensation and quadrants: 
 Unstained cells (negative control, FITC negative and PI negative; will be 
in lower left quadrant of histogram); 
 Untreated cells stained with Annexin V-FITC alone, but not PI (to give 
background or nonspecific Annexin V-FITC staining; will be in lower 
right quadrant); 
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 Untreated cells stained with PI alone, but not Annexin V-FITC (to give 
background or nonspecific PI staining; will be in upper left quadrant); 
 Apoptosis-induced cells (positive control; will be in upper right quadrant). 
Apoptotic cells can be induced by multiple methods and in our research we used 
Camptothecin (Sigma-Aldrich); it is a cytotoxic quinoline alkaloid extracted from the 
bark and stem of the Chinese tree Camptotheca acuminata, and  has been shown to 
induce apoptosis in a dose-dependent manner in vitro, due to its action as a potent 
inhibitor of the DNA enzyme  topoisomerase (Topo I), a molecule required for DNA 
synthesis.  
After performing a time course with different Camptothecin concentrations, the 
protocol that gave us optimal results was as follows for Camptothecin-induced apoptosis: 
1. Prepare a 1 mM stock solution of Camptothecin (Sigma Cat. No. C-9911) in 
DMSO. 
2. Add 6 µM (final concentration) Camptothecin to cell suspension (1x 106 cells/ml 
in cell culture medium). 
3. Incubate for 6 hr at 37°C. 
4. Proceed with assays designed to evaluate induction of apoptosis. 
After apoptosis induction, generating apoptotic cells which will serve as a positive 
control, cells under different conditions are prepared for the staining procedure: 
  Negative control (uninfected Jurkat cells); 
 Positive control (apoptotic jurkat cells induced by Camptothecin); 
 Uninfected Jurkat cells treated with DEX/DEAE; 
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 Untreated Jurkat cells infected with HIV; 
 Jurkat cells infected with HIV and treated with DEX/DEAE. 
The experimental staining procedure was as follows: 
1. Wash Jurkat cells twice with cold phosphate-buffered saline (PBS) and then 
resuspend cells in 1X Binding Buffer at a concentration of ~1 x 106 cells/ml. 
2. Transfer 100 µl of the solution (~1 x 105 cells) to a 5 ml culture tube. 
3. Add Annexin V and Vital Dye: FITC 5 uL, PI 2 uL. 
4. Gently mix the cells and incubate for 15 min at RT in the dark. 
5. Add 400 µl of 1X Binding Buffer to each tube.  
Finally, the samples were analyzed using BD FACSAria III flow cytometer within 1 
hour, a high performance flow cytometer analyzer and cell sorter. 
 Results 
The mechanism by which the flowcytometer works is that when a cell passes 
through a laser beam in the flow cytometer, it generates light scatter. Forward scatter 
(FSC) provides information about the cell size, while side scatter (SSC) gives 
information about the cells morphological complexity, in fact cell shrinkage and 
increased granularity can be analysed following the FSC and SSC criteria respectively 
[26]. Due to the morphological changes the cell undergoes after death, there are changes 
in light scatter that follow and may reflect these phenomena, and these changes differ 
from apoptosis and necrosis as follows: 
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 Necrosis: both FSC and SSC increase, as a consequence of cell engorgement. 
 Apoptosis: FSC and SSC decrease as a consequence of plasma membrane damage 
and leakage of cell constituents.  
 
Figure 19: Flow cytometric analyses (FACS) measuring apoptosis (A, B, C, D and E).  
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Figure 19 shows representative scatter plots for propidium iodide (PI) (y-axis) versus 
Annexin V-FITC (x-axis), with different cell treatments (A-E). Lower left quadrants 
(absence of both markers) indicate viable cells; upper left quadrants (PI positive) indicate 
cellular necrosis. Lower right quadrants (PI negative, FITC positive) indicate early stage 
apoptosis; upper right quadrants (PI positive, FITC positive) indicate late stage apoptosis. 
The various treatments are:  A: Negative control (uninfected Jurkat cells); B: Uninfected 
Jurkat cells treated with DEX/DEAE; C: Positive control (apoptotic jurkat cells induced 
by Camptothecin); D: Jurkat cells infected with HIV only (no drugs); E: Jurkat cells 
infected with HIV and treated with DEX/DEAE. 
The results shown above represent an average of triplicates of each sample, and 
we can see how the cell viability (percentage of cells in the lower left quadrant of each 
histogram) in the uninfected Jurkat cells after 24 hrs treatment with the combination of 
DEX/DEAE (B) is not disturbed and remains at 89% compared to the negative control 
(A) that is at 92%, while the DEAE/Dex treated HIV infected Jurkat cells (E) reach a 
viability of only 47% compared to a viability in untreated HIV-infected cells (D) with no 
treatment of 77% (showing that some cell death is induced by the virus alone). In both 
case however, the cell death at the time point measurements were taken appears to be 
predominantly early apoptotic. 
The same experiment was repeated on a different cell line CEM-SS and the 
results were read using a FACSCalibur flow cytometer (Becton Dickinson Biosciences, 
San Jose, CA) equipped with a 488-nm argon laser.  
 
Figure 20: Flow cytometry results: 
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In figure 19 it is important to note that the axes have changed: PI is on x-axis, Annex V-
FITC is on y-axis. Lower left quadrants, viable cells. Lower right quadrants, necrotic 
cells. Upper left quadrants, early apoptotic cells. Upper right quadrants, nonviable late 
apoptotic cells. For the positive control, apoptosis was induced using Camptothecin. Note 
that in the presence of Dex/DEAE, early apoptosis is considerably increased in HIV+ 
cells.  
The results shown above are in accordance with the previous experiment, showing 
a total cell death of only 10.26% in the uninfected CEM-SS cells treated with 
Dex/DEAE, compared to 0.15% in the negative control (untreated, uninfected cells), 
while the HIV infected cells treated with Dex/DEAE showed a 60.34% rate of apoptosis 
and 11.36% necrosis, compared to 24.83% apoptosis and 13.40% necrosis in the HIV 
infected untreated cells. 
 Double Stain Apoptosis Detection Assay (Hoechst 33342/PI) 
The previous Flow Cytometry experiments used populations of cells that in the 
case of “HIV+ cells” nonetheless contained a mixed population of infected and 
uninfected cells (because not all cells are infected even though the cultures were 
innoculated with virus). Thus, we desired to study the phenomenon of Dex/DEAE 
induced apoptosis in a population of sorted, uniformly infected cells.  
 Materials and Methods 
For that purpose we used CEM-GFP cells that have the property of producing 
GFP post infection as a marker to differentiate between HIV+ and HIV- cells. For this, 
we used a BD Biosciences FACSAria III cell sorter which is considered to be BD’s most 
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advanced cell sorter.  FACS (Fluorescence-Activated Cell Sorting) is a method for 
separating particles from a heterogeneous suspension to one that is homogeneous based 
on the physical and fluorescent properties of the particles established by flow cytometric 
analysis of samples. 
We used a cell density of 10 x 106 cells/ml filtered through a 40 µm filter, and made sure 
that the cells were as healthy as possible, as the healthier they are, the better they will 
hold up after the sorting process. The cells were prepared in a final suspension buffer that 
contains 2% serum; it is important that the serum is limited to a small amount because 
high serum concentrations cause distortion of light scatter signals.  
RPMI medium containing 10% serum was prepared and added to the collection tubes so 
that cells remain as healthy as possible after the sort, and were transported immediately 
after the sort in a sterile manner and plated into microplates. 
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 Figure 21: Schematic representing the mechanism of Flow Cytometry and Flourescence-
Activated Cell Sorting (FACS) [27] 
 
Furthermore, different cell types sort differently, so we had to proceed with multiple sorts 
to optimize conditions for the CEM-GFP cells. 
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The optimal parameters for CEM-GFP cells were as follow:  
The FACSAria has two nozzle sizes, 70 um and 100 um. To achieve good stream 
stability, it is suggested that the cells being sorted should be 1/4  to 1/5 the size of the 
nozzle; this is important because it gives the FACSAria an effective limit on sorting cells 
below 50 um in diameter. That is why we chose the 70um nozzle, since our CEM-GFP 
are about 12um in diameter. By choosing the 70 um nozzle, we had to keep in mind that 
the stability of the stream is related to the nozzle size. and using the 70 um nozzle, the 
instrument is stable at 70 PSI (high pressure sort). 
At 70 psi and 90 kHz with an average threshold rate of 25,000 events per second, 
a two-way sort achieved a purity of >94% and a yield >80% of Poisson’s expected yield 
as shown in figure 22. All sorts were performed at sheath pressure of 70 PSI using CEM-
GFP cell line, and resulted in cells that proved to be viable and proliferated for several 
days post-sort. 
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Figure 22: Purity of CEM-GFP cells pre sort (left) and post sort (right) 
 
The Double Stain Apoptosis Detection Kit (Hoechst 33342/PI) was chosen because it 
provides a rapid and convenient assay for apoptosis based upon fluorescent detection for 
the compacted state of the chromatin in apoptotic cells, especially because it is based on 
two ready-to-use dyes bound to DNA:  
 Hoechst 33342: a blue-fluorescence dye (excitation/ emission maxima ~350/461 
nm when bound to DNA), stains the condensed chromatin in apoptotic cells more 
brightly than the chromatin in normal cells.  
 Propidium iodide (PI): a red-fluorescence dye (excitation/emission maxima 
~535/617 nm when bound to DNA), is only permeant to dead cells.  
With these two dyes that have excitation/emission maxima different from the GFP range 
it will be easy to distinguish between the three fluorecent dyes after analysis. 
Furthermore, the staining pattern produced by the simultaneous use of these dyes makes 
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it possible to distinguish normal, apoptotic, and dead cell populations by flow cytometry 
and fluorescence microscopy. 
Protocol: 
1. Prepare a positive control: induce apoptosis in cells using Camptothecin.  
1. Prepare a negative control without inducing reagent. 
2. Wash the CEM-GFP cells by cold PBS and adjust the cell density to 1×106 
cells/ml in PBS. 
3. Directly collect suspension cells by centrifugation. 
2. Add 10 μl of Hoechst 33342 to each 1 ml of the cell suspension and mix 
thoroughly. Incubate the cells at 37°C for 5-15 minutes. 
3. Centrifuge the cells at 1,000 rpm for five minutes at 4°C and discard the 
supernatant. 
4. Resuspend cells in 1000 μl of 1X buffer A. 
5. Add 5 μl of PI to each 1 ml of cell suspension and mix thoroughly. Incubate the 
cells at room temperature for 5-15 minutes and avoid exposing to light. 
6. Post incubation, analyze the stained cells by flow cytometry immediately, using 
UV/488 nm dual excitaiton and measuring the fluorescence emission at ~460 nm 
emission of Hoechst 33342 dye and >575 nm emission of Propidium Iodide.  
After this step the population can be separated into three groups: live cells will show only 
a low level of fluorescence; apoptotic cells will show a higher level of blue fluorescence, 
and dead cells will show low-blue and high-red fluorescence.  
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The flow cytometer results were confirmed by viewing the cells under a fluorescence 
microscope. 
 Results 
The flow cytometer results showed an apparent shift in the Hoechst 33342 
absorbance in the cells infected by HIV (Figure 23), proving that the cells are dying via 
apoptosis and the most pronounced effect was noticed in the HIV infected cells treated 
with Dexamethasone and DEAE, while the cells that were infected with the virus but did 
not receive any treatment showed a shift characterizing the cell death induced by the 
virus itself. The non infected cells treated with Dexamethasone and DEAE did not appear 
any different than the non treated cells, reinforcing our previous findings that the 
combination is non toxic to the non infected cells, and the apoptosis inducing effect is 
only witnessed in the infected cells. 
 
 
 
Histogram Statist
Marke Left, Righ Events % Gate % Tota Mean CV MedianPeak C
All    1,  991 6339 100.00 63.39 10.29 206.73 6.49 7
M1    1,    4509 71.13 45.09 5.36 36.06 5.33 7
M2    9,   14 1698 26.79 16.98 19.12 113.53 12.52 9
File: neg control.001 Acquisition Date: 02-Ma
Gate: G1 Gated Events: 6339
Total Events: 10000
Figure 23: Histogram representation of Hoechst fluorescence representing apoptosis. 
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The cells were further analyzed by the FACS to look for the combined fluorescence of 
both Hoechst 33342 and PI. Figure 24 shows the results collected, and as shown by the 
statistics the HIV infected cells treated with Dex/DEAE have 47.2% of the total cell 
population at a late apoptosis stage and 20.19% early apoptotic, while the non infected 
cells treated with Dex/DEAE showed 15.35% early apoptotic and an insignificant number 
of cells dead via late apoptosis, and the HIV infected cells untreated had a 19.29% cell 
death slightly higher than the uninfected cells, which represents the effect of the virus on 
the cells. 
 
 
 
Figure 24: FACS results of Hoechst and PI combined for : 
Upper left: control non infected non treated cells. 
Upper right: non infected cells treated with DEX/DEAE. 
Lower left: apoptosis induced cells via camptothecin. 
Lower right: HIV infected cells treated with DEX/DEAE. 
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Discussion 
The results collected by  flow cytometry   indicated  that the combination of the 
two FDA approved drugs appears  to be a potent inducer of programmed cell death  
(apoptosis) only in infected cells (killing almost 50% of the total HIV+ population) while 
non infected cells seem to be relatively unaffected by this combination. This suggests that 
Dex+DEAE triggers genes and biochemical pathways that lead to apoptosis as a response 
to the HIV infection in cells, and it is of great interest to identify these genes and 
pathways to further analyze and understand this effect. Microarray analysis seems to be 
the perfect method for this endeavor.
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CHAPTER VII 
DNA MICROARRAYS AND GENES INVOLVED 
A more comprehensive picture of the mechanism can be obtained by comparing 
whole-genome MicroArray data. This gene expression analysis gives us a better 
understanding of the molecular logic underlying biological circuits involved in this 
mechanism of selective toxicity induced by Dex/DEAE. 
Historically the use of microarray has led to the understanding and discovery of 
many molecular mechanisms underlying normal and dysfunctional biological processes 
that play important roles in cell performance of many diseases.  
Microarray studies along with other genomic techniques represent an important 
stimulant in drug development, immunotherapeutics and gene therapy. However, 
microarray techniques have an advantage over other techniques that were employed for 
determining gene expression levels, such as Northern Blot analysis, because the later 
have been limited to the gene-by-gene approach, by looking for transcripts (certain RNA 
expression levels) one or a few at a time [28]. The invention of genome-wide transcript 
screening methods such as DNA microarray technology have  helped surmount this 
restraint, and opened the door for scientists to study thousands of transcripts 
simultaneously [29].
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Materials and Methods 
Microarray is a high-throughput technology that uses an ordered array of 
microscopic elements on a planar substrate that allows the specific binding of analytes 
(molecules under analysis) [29], enabling the measurement of thousands of genes in a 
single RNA sample.  Microarrays contain assortments of small components or spots 
arranged in rows and columns, and during measurements, the array is exposed to the 
biological sample (generally in an aqueous solution) where different analytes are present 
in unknown concentrations. Individual spots then capture specific analytes by affinity 
from the solution in the incubation phase and consequently the quantity captured is 
measured in real time or at the end of incubation depending on the method[29]. 
The microarray systems that measure mRNA concentrations are referred to as 
DNA microarrays or gene chips. They are ordered collections of DNA sequences 
(probes) deposited on and chemically bound to solid surfaces such as microscope slides 
(see Fig25). 
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Figure 25: Affymetrix gene chip[30]. 
 
 
Although there are a variety of microarray platforms that have been developed and 
evolved significantly since their introduction in 1995[31], the most popular format is still 
the original gene expression microarray designed to measure the relative abundance of 
mRNA transcripts. 
DNA microarrays are based on the principle of DNA hybridization, by which a 
single strand of DNA (the probe) binds to a complementary strand of DNA (the target), 
forming a highly stable duplex structure in a lower energy state [29].  
To allow detection of this hybridization, targets are fluorescently labeled with 
fluorophore molecules (such as Cy3 and Cy5 dyes)[32] 
A typical microarray detection procedure follows this basic methodology:  
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1. A slide or membrane is spotted or "arrayed" with DNA fragments or 
oligonucleotides that represent specific gene coding regions.  
2. RNAs are initially reverse transcribed into cDNA by a simple polymerization 
reaction 
3. RNA is purified and then fluorescently- or radioactively labeled  
4. The prepared RNA is simultaneously hybridized to the slide/membrane.  
5. The microarrays are thoroughly washed to eliminate any excess from the 
hybridization reaction then dried.  
6. The raw data is obtained by laser scanning or autoradiographic imaging for 
detection of fluorescence on the DNA probes as represented in Figure 1).  
7. The intensity in each spot is related to the expression level of the specified gene, 
and the data is then entered into a database and analyzed by multiple statistical 
methods.[33] 
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Figure 26: (A) A microarray may contain thousands of spots. Each spot contains many 
copies of the same DNA sequence that uniquely represents a gene from an organism. 
Spots are arranged in an orderly fashion into Pengroups.  (B) Schematic of the 
experimental protocol to study differential expression of genes. The organism is grown in 
two different conditions (a reference condition and a test condition). RNA is extracted 
from the two cells, and is labelled with different dyes (red and green) during the synthesis 
of cDNA by reverse transcriptase [34]. 
 
 
Following this step, cDNA is hybridized onto the microarray slide, where each 
cDNA molecule representing a gene will bind to the spot containing its complementary 
DNA sequence. The microarray slide is then excited with a laser at suitable wavelengths 
to detect the red and green dyes. The final image is stored as a file for further analysis 
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[35]. For our experiment we prepared the samples according to the selective toxicity 
protocol briefly as follows:  
• Culture Jurkat cells on microplates. 
• Infect half of the cells with HIV-1, leave half uninfected; incubate for 12 hours.  
• Expose both groups of cells to various treatments: 
o No drugs.  
o Combination of Dex and DEAE.   
• After 48 hours incubation, the total cellular RNA is prepared and purified using 
TRIzol® Plus from Invitrogen which is considered the most trusted reagent for 
preparing high quality, intact RNA from cells. The TRIzol® Plus combines the 
property of TRIzol® Reagent to efficiently lyse tissues and cells with the silica 
spin-column for the isolation of total RNA using the PureLink™ RNA Mini Kit. 
Total RNA extracted from the samples was checked for purity using a spectrophotometer 
to quantify the amount of nucleic acids via UV absorption measured at the wavelengths 
of 260 nm and 280. A260 is frequently used to measure RNA concentration since RNA 
has its absorption maximum at 260 nm and A280 is used to measure protein 
concentration. A ratio of A260/A280 > 1.8 suggests little protein contamination in an 
RNA sample, and the concentration of nucleic acid can be determined using the Beer-
Lambert law, which predicts a linear change in absorbance with concentration, and pure 
RNA has an A260/A280 of 2.1 [33]. In many protocols it is indicated that a value 
between 1.8 and 2.0 indicates that the RNA is pure. 
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Our samples had A260/A280 ratio of 2, and were then packaged in 1.5 ml RNase-
free microcentrifuge tubes, containing 35µg each of high quality total RNA in 100µl 
DEPC-treated water. The prepared total RNA was sent to The Microarray Shared 
Resource of the Comprehensive Cancer Center of Wake Forest University (CCCWFU) 
directed by Dr. Lance Miller, Associate Professor, Department of Cancer Biology.  The 
samples were run on Affymetrix HG-U133 Plus 2.0 chips using GeneChip Scanner 3000 
7G multi-color scanner. 
Further quality control checks were run on all samples by the Wake Forest Core 
facility, and the quality and quantity of RNA was judged acceptable. The core facility 
provided us with Excel tables that show the prospective intensities of each one of our 
samples: 
o Uninfected cells non treated 
o Uninfected cells treated with DEX/DEAE 
o Infected cells untreated 
o Infected cells treated with DEX/DEAE 
And from there we analyzed the microarray data which represented a huge challenge for 
us due to the colossal amount of data generated by this powerful technology; the analysis 
of the 60,000 genes was done using R software. 
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Microarray Data Analysis 
 Systematic variation between experimental conditions are unrelated to the 
biological differences we seek in a microarray analysis, that is why a normalization step 
is crucial to the analysis as it accounts for these differences and compensates for any 
systematic technical differences between chips, to allow us observe more clearly the 
systematic biological differences between our biological samples [36].  
Many commercially or freely available tools exist to perform the common steps 
for analyzing microarray data; we chose to use BRB-ArrayTools by Richard Simon and 
BRB-ArrayTools Development Team at the National Cancer Institute, NIH Bethesda. 
BRB-ArrayTools is an integrated package for the visualization and statistical analysis of 
DNA microarray gene expression data. It was developed by professional statisticians 
experienced in the analysis of microarray data and involved in the development of 
improved methods for the design and analysis of microarray based experiments [37]. The 
array tools package utilizes an Excel layout that we are familiar with. 
An important part of the microarray analysis includes the comparison of the 
differentially expressed genes or the change of certain expression levels in the different 
array corresponding to the different conditions used. 
For this purpose the arrays have to be comparable. However different arrays have 
different intensity levels, also if the same condition is measured twice and the average 
intensity is the same, the distribution of intensity values may differ, [38], the difference in 
intensity in raw data (figure 27) cannot be taken into consideration until after 
normalization: 
72 
 
 
Figure 27: Box plot representation of the dispersion of raw data intensities: 
Rows1,2,3,4,5 represent the different sample treatments in the experiment; Row1: 
uninfected untreated Jurkat cells; Row2: HIV infected Jurkat cells treated with 
Dex/DEAE; Row3: uninfected,Jurkat cells treated with Dex/DEAE; Row 4: HIV infected 
untreated Jurkat cells; Row5: HIV infected treated with Gentamicin cells (irrelevant for 
our experiment, belongs to another experiment but data was still used for normalization 
purposes). 
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Figure 28: Histogram presentation of Log2 intensities of raw data. 
Only the three important conditions in the experiment were used for the Log2 
normalization: Blue represents uninfected untreated Jurkat cells; red represents 
uninfected Jurkat cells treated with Dex/DEAE; green represents HIV infected Jurkat 
cells treated with Dex/DEAE. 
 
 
In general, to obtain single gene expression value out of raw probe intensity 
measurements is called "microarray preprocessing",  in order to be able to consider these 
results valid it is critical to proceed with pre-processing and normalization of microarray 
data, in order tocontrol the effects of systematic error while retaining full biological 
variation [34].  
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Many different normalization methods or combinations of methods were proposed 
over the years, for our analysis we chose the three most reliable methods: Systematic 
Variation Normalization (SVN), Robust Multi-array Analysis (RMA) and the standard 
Affymetrix probe modeling algorithm MAS5: 
 Systematic variation normalization (SVN) is a procedure for removing systematic 
variation in microarray gene expression data. This technique is based on an 
analysis of systematic variation as it contributes to variability in microarray data 
sets; it contains background subtraction determined by the distribution of pixel 
intensity values and log conversion, linear or non-linear regression, restoration or 
transformation, and multiarray normalization [39] 
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Figure 29: Box plot presentation of data intensities after SVN normalization (see 
Figure 25 for explanation of treatments represented by the various rows). 
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Figure 30: Histogram presentation of Log2 intensities after SVN normalization (see 
figure 28 for explanation of color coding). 
 
 
 RMA (Robust Multi-array Analysis) is a method for normalizing and 
summarizing probe-level intensity measurements from Affymetrix Gene Chips ®, 
it actually has become the de facto standard for preprocessing expression data 
from Affymetrix GeneChips. It uses probe-level expression measurements of all 
arrays to estimate expression values, starting with the probe-level data from a set 
of Gene Chips, the perfect-match (PM) values are background-corrected, 
normalized and finally summarized resulting in a set of expression measures. It 
comprises the three steps: Background Correction, Normalization and 
summarization [40]. 
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Figure 31: Box plot representation of data intensities after RMA normalization (see 
Figure 27 for explanation of treatments represented by the various rows). 
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Figure 32: Histogram presentation of Log2 intensities after RMA normalization (see 
figure 28 for explanation of color coding). 
 
 
 The standard Affymetrix probe modeling algorithm MAS5: is a basic method 
considered just slightly better than scaling using linear regression. This procedure 
is to construct a plot of each chip's probes against the corresponding probes on the 
baseline chip; eliminate the highest 1% of probes (and for symmetry the lowest 
1%), and fit a regression line to the middle 98% of probes (ie. estimate slope and 
intercept: two parameters). Transform the values in each probe, by subtracting the 
intercept, and dividing by the slope, so that the regression line becomes the 
identity ( y = x ) line [36]. 
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Figure 33: Box plot representation of data intensities after MAS5 normalization (see 
Figure 27 for explanation of treatments represented by the various rows). 
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Figure 34: Histogram presentation of Log2 intensities after MAS5 normalization (see 
figure 28 for explanation of color coding). 
 
 
These three pre-processing methods have in common the ability to remove systematic 
variation in the data attributable to variability in microarray slides, assay-batches, the 
array process, or experimenters. Biologically meaningful comparisons of gene expression 
patterns between control and test channels or among multiple arrays are therefore 
unbiased using normalized datasets [41]. 
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Results 
After the analysis of the Microarray data  compiled via the three different 
normalization methods, altered expression of  several genes  in the HIV infected cells 
treated with Dexamethasone and DEAE was revealed; 211 genes upregulated and 91 
down regulated (figure 35), while the uninfected cells treated with Dexamethasone and 
DEAE showed 1 up regulated gene , and 29 down regulated (figure36). A complete list of 
the genes affected is listed in the appendix. 
 
 
Figure 35: Genes up and down regulated in HIV+ Jurkat cells treated with Dex/DEAE. 
Space does not permit the labeling of individual genes, which are listed in rank order in 
the appendix. 
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Figure 36: genes up and down regulated in the HIV- Jurkat cells treated with 
Dex/DEAE. 
 
 
It is beyond the scope of the current project to conduct a complete analysis of this 
data set (which requires software for “Systems Biology” pathway analysis that we do not 
possess), we proceeded with a preliminary manual analysis of all these genes, to be able 
to single out specific genes and or clusters of genes belonging to gene networks 
(biochemical pathways) that are induced or down regulated only in the presence of both 
drugs and virus and which therefore could be central to the mechanism of selective 
toxicity to infected cells. (Already stated) We also looked for genes that might relate to 
the experimental evidence presented previously, e.g., suggesting that Dex/DEAE 
achieves its effects via the induction of apoptosis in HIV-infected cells (Chapter 6). 
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A handful of upregulated genes are specifically involved in apoptosis.  These 
include Annexin A1 (ANXA1), which is related to the Annexin V that we used as a 
fluorophore in Chapter 6 to demonstrate apoptosis using flow cytometry.  Another is 
Mudeng (“MU-2/AP1M2 domain containing, death-inducing”), a gene that encodes a 
protein that is known to induce cell death in cytotoxic T cells. Other important cell-death 
related genes that are upregulated include BCLAF1, which when overexpressed is 
proapoptotic via its action as a transcriptional repressor of BCL-2 family genes, and last 
but not least, Fas (CD95), a well known inducer of cell death [42, 43] [44]. 
Various other up- or downregulated genes are, if not directly involved in 
apoptosis, possibly indirectly involved via their roles in the cell growth cycle, e.g. 
hedgehog interacting protein (HHIP, upregulated); alpha thalassemia/mental retardation 
syndrome X-linked (ATRX, upregulated), a transcription factor involved in cell cycle 
progression from G1 to S phase, and cyclin-dependent kinase inhibitor 2D (CDKN2D, 
downregulated), a cell growth regulator that controls cell cycle G1 progression [42]. 
Several notable clusters of genes whose functions can also be related to apoptosis 
include: 
1. A set of peptidyl-prolyl isomerases (PPIs, often called cyclophilins, including 
PPIG, PPIL1, PPWD1, all upregulated),  
2. Several ubiquitin-related genes (USP15 and USP16, both upregulated), and  
3. A group of genes involved in regulation of RNA splicing (splicing factors SFRS7, 
11, 12, 18, all upregulated).  
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The peptidyl-prolyl isomerases may have functions that relate to pre-mRNA 
splicing (e.g. PPWD1 can be part of the spliceosome) [45, 46]. The splicing-related genes 
may relate to the Fas death pathway, because splicing can produce FLIPs, the short form 
of FLICE inhibitor [47].  Furthermore, the half life of certain protein isoforms is 
regulated by degradation via ubiquitination, possibly explaining cluster of ubiquitin-
related genes. For example, USP15 directly regulates Caspase 3, and important mediator 
of apoptotic signaling [48]; furthermore, the short form of FLICE inhibitor mentioned 
above is degraded via ubiquitination faster than the long form, which links ubiquitination 
as well as RNA splicing to the regulation of apoptosis. Thus, the net effect of this cluster 
of genes may be to reduce the half life of an inhibitor of Fas, which combined with 
increased Fas expression, accelerates cell death [49]. 
Thus, it appears upon preliminary examination that the results of the microarray 
study are reasonably consistent with the experimental results reviewed previously. 
However, a more in depth computer assisted analysis, will be required to fully mine the 
microarray data set for clues as to the exact mechanism by which the intersection of HIV 
infection plus Dex/DEAE treatment selectively unleashes apoptosis in cells.
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CHAPTER VIII  
SUMMARY AND FUTURE RESEARCH DIRECTIONS 
 
 
Summary 
 
The results described in this dissertation are a proof of concept and support to the 
hypothesis that there are two complementary modes of action of the Dex/Procaine or 
Dex/DEAE drug combinations:  
1. the ability to inhibit viral replication, most effectively at low viral titers (this is 
most likely due to the documented NF-B antagonism of Dex) 
2. the ability to selectively kill HIV-infected cells.  
This is a very unique activity and has rarely been reported, particularly for small 
molecule drugs. It is expected that with prolonged exposure to treatment with this drug 
combination, the killing of infected cells would lead to a decline in viral load. This has 
been confirmed in the experiments described at the end of Chapter IV. Over just a two-
week period, viral load was decreased by more than 50%, compared to untreated infected 
cells. This reduction in viral titer by the proposed mechanism of selective killing of HIV-
infected cells would be expected to enhance the effectiveness of the treatment to inhibit 
HIV replication, which is more effective at low viral titers (Chapter IV). Thus, these two 
activities could be synergistic in practice. Furthermore, the drug combination showed an 
additive effect when combined with an antiretroviral drug (AZT), and the antiviral 
activity of the Pro/Dex combination remained unchanged in an AZT-resistant strain of
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 HIV, suggesting that the treatment is likely to be effective against other common drug-
resistant strains.   
We have used 3 independent methods to confirm that the Dex/DEAE combination 
leads to a selective reduction in the number of viable cells in HIV-infected Jurkat cells:  
MTT assay, XTT assay (Chapter III) and fluorometric Live/Dead cell assays (Chapter V). 
Combined with evidence that, over time, the viral titer decreases in infected cells exposed 
to this treatment, compared to untreated infected cells (Chapter IV), these results strongly 
suggest that it is HIV-infected cells that are being selectively eliminated by the drug 
treatment.  
To shed the light on the mechanism of cell death involved, several flow cytometric 
techniques were used (Chapter VI).  These studies demonstrate that the HIV infected 
cells are selectively killed by Dex/DEAE by the induction of apoptosis, via several 
known apoptotic pathways that we have identified using microarray analysis techniques 
(Chapter VII). Significantly, in one study (Figure 26, Chapter VI), it was demonstrated 
that in a uniformly infected population of cells (almost 100% infected cells, generated by 
cell sorting using a FACS ARIA III), the drug treatment induced a state of early or late 
apoptosis in over 67% of the cells, whereas drug treated uninfected cells showed only a 
5% increase in apoptosis relative to untreated uninfected cells (15% vs. 10% 
respectively).  This definitively demonstrates that the drug treatment effectively targets 
HIV-infected cells for apoptosis, while having little effect on uninfected cells. 
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Q.E.D. 
Future Research Directions 
 Q-PCR/RT PCR 
 Results obtained from MicroArray studies can be confirmed using real-time PCR 
or quantitative PCR to get more accurate quantitative readings of how the expression of 
specific genes changes in response to the various treatments. So after we identify the 
genes in question, we will prepare total RNA from the samples (Untreated control cells, 
cells treated with either virus or drugs alone, and cells treated with both virus and drugs) 
using Qiagen’s Rneasy Kit; cDNAs will be prepared by using Qiagen’s Quantitect 
Reverse transcription kit.  Target gene expression will be determined by SYBR Green 
PCR. The specific primers for PCR will be picked from NIH PrimerDepot at 
http://primerdepot.nci.nih.gov/. The real time PCR products will be quantitated by 
generating a standard curve or quantitated relative to a control gene. From these results 
we shall be able to detect any abnormality to confirm the results generated with Micro 
array. 
 RNAi 
The biochemical effects of the changes induced by DEAE/Dex in gene expression can be 
studied using RNA interference particularly short interfering RNAs (siRNA) to mimic a 
gene that is down regulated, so we will design and generate (siRNAs) against the specific 
genes that proved to be down regulated from the results collected through Microarray and 
real time PCR, and we will use a transfection reagent to get the siRNAs inside the cells, 
such as LipofectAMINE from INVITROGEN, and then since RNAi down regulates a 
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gene function without actually interacting with it, but via mRNA degradation, we can 
actually measure  the degree of RNA interference achieved, by directly relating it to the 
level of mature mRNA and the translated proteins. The mature mRNA can then be 
measured by quantitative PCR using SYBR green since it is the most sensitive method 
and can discriminate closely related mRNAs. 
 By the same rationale we can mimic a gene that is upregulated by gene 
transfection/expression. We will transfect cells with the target gene to see if it inhibits 
HIV replication. Briefly, CEM cells are plated in a 24-well plate. Cells are transfected 
with the target gene expression vector, using an empty vector as control. 6 hours post-
transfection, cells are infected with HIV-1 stock (MOI=0.1). 48 hours post-infection, 
luciferase activity is measured. Luciferase activity of CEM cells is used to give 
comparative levels of virus replication, at varied levels of the transfected gene. This 
experiment can establish whether the gene under study could be an intermediary between 
exposure to the drugs (Dex/DEAE), and increased HIV production in the infected cell. 
And if this approach leads to the expected result (e.g., cell death by apoptosis), we will 
have a plausible mechanism for how the drug treatment exerts its unique effects in HIV-
infected cells.
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APPENDIX A 
GENES AFFECTED IN INFECTED CELLS  
 WITH DEX/DEAE 
List of Upregulated genes arranged in decreasing intensity: 
Probe Set ID | Gene Symbol | Gene Title 
218718_at | PDGFC | platelet derived growth factor C 
206727_at | C9 | complement component 9 
218886_at | PAK1IP1 | PAK1 interacting protein 1 
204614_at | SERPINB2 | serpin peptidase inhibitor, clade B (ovalbumin), member 2 
234989_at | NEAT1 | nuclear paraspeckle assembly transcript 1 (non-protein coding) 
223154_at | MRPL1 | mitochondrial ribosomal protein L1 
223809_at | RGS18 | regulator of G-protein signaling 18 
231175_at | BEND6 | BEN domain containing 6 
1554089_s_at | SBDS /// SBDSP | Shwachman-Bodian-Diamond syndrome /// 
Shwachman-Bodian-Diamond syndrome pseudogene 
232231_at | RUNX2 | runt-related transcription factor 2 
222808_at | ALG13 | asparagine-linked glycosylation 13 homolog (S. cerevisiae) 
232063_x_at | FARSB | phenylalanyl-tRNA synthetase, beta subunit 
212718_at | PAPOLA | poly(A) polymerase alpha 
208835_s_at | LUC7L3 | LUC7-like 3 (S. cerevisiae) 
224632_at | GPATCH4 | G patch domain containing 4 
203176_s_at | TFAM | transcription factor A, mitochondrial 
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1558111_at | MBNL1 | muscleblind-like (Drosophila) 
201593_s_at | ZC3H15 | zinc finger CCCH-type containing 15 
215171_s_at | TIMM17A | translocase of inner mitochondrial membrane 17 homolog A 
(yeast) 
201012_at | ANXA1 | annexin A1 
234405_s_at | PHAX | phosphorylated adaptor for RNA export 
208859_s_at | ATRX | alpha thalassemia/mental retardation syndrome X-linked (RAD54 
homolog, S. cerevisiae) 
235925_at | TCF12 | Transcription factor 12 
205518_s_at | CMAH | cytidine monophosphate-N-acetylneuraminic acid hydroxylase 
(CMP-N-acetylneuraminate monooxygenase)  
235879_at | MBNL1 | Muscleblind-like (Drosophila) 
1557081_at | RBM25 | RNA binding motif protein 25 
1564164_at | DENND1B | DENN/MADD domain containing 1B 
1559094_at | FBXO9 | F-box protein 9 
212720_at | PAPOLA | poly(A) polymerase alpha 
218859_s_at | ESF1 | ESF1, nucleolar pre-rRNA processing protein, homolog (S. 
cerevisiae) 
201110_s_at | THBS1 | thrombospondin 1 
227062_at | NEAT1 | nuclear paraspeckle assembly transcript 1 (non-protein coding) 
222850_s_at | DNAJB14 | DnaJ (Hsp40) homolog, subfamily B, member 14 
213649_at | SFRS7 | splicing factor, arginine/serine-rich 7, 35kDa 
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217147_s_at | TRAT1 | T cell receptor associated transmembrane adaptor 1 
201821_s_at | TIMM17A | translocase of inner mitochondrial membrane 17 homolog A 
(yeast) 
222669_s_at | SBDS /// SBDSP | Shwachman-Bodian-Diamond syndrome /// 
Shwachman-Bodian-Diamond syndrome pseudogene 
206660_at | IGLL1 | immunoglobulin lambda-like polypeptide 1 
217850_at | GNL3 | guanine nucleotide binding protein-like 3 (nucleolar) 
214662_at | WDR43 | WD repeat domain 43 
218386_x_at | USP16 | ubiquitin specific peptidase 16 
200685_at | SFRS11 | splicing factor, arginine/serine-rich 11 
218535_s_at | RIOK2 | RIO kinase 2 (yeast) 
235469_at | FAM133B | family with sequence similarity 133, member B 
201699_at | PSMC6 | proteasome (prosome, macropain) 26S subunit, ATPase, 6 
226269_at | GDAP1 | ganglioside-induced differentiation-associated protein 1 
213899_at | METAP2 | methionyl aminopeptidase 2 
210793_s_at | NUP98 | nucleoporin 98kDa 
203584_at | TTC35 | tetratricopeptide repeat domain 35 
221970_s_at | NOL11 | nucleolar protein 11 
217987_at | ASNSD1 | asparagine synthetase domain containing 1 
227322_s_at | BCCIP | BRCA2 and CDKN1A interacting protein 
202541_at | AIMP1 | aminoacyl tRNA synthetase complex-interacting multifunctional 
protein 1 
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209181_s_at | RABGGTB | Rab geranylgeranyltransferase, beta subunit 
201595_s_at | ZC3H15 | zinc finger CCCH-type containing 15 
210681_s_at | USP15 | ubiquitin specific peptidase 15 
212893_at | ZZZ3 | zinc finger, ZZ-type containing 3 
230097_at | GART | Phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole  
1553689_s_at | METTL6 | methyltransferase like 6 
203023_at | NOP16 | NOP16 nucleolar protein homolog (yeast) 
203177_x_at | TFAM | transcription factor A, mitochondrial 
224870_at | KIAA0114 | KIAA0114 
228050_at | UTP15 | UTP15, U3 small nucleolar ribonucleoprotein, homolog (S. 
cerevisiae) 
219212_at | HSPA14 | heat shock 70kDa protein 14 
213092_x_at | DNAJC9 | DnaJ (Hsp40) homolog, subfamily C, member 9 
1559096_x_at | FBXO9 | F-box protein 9 
213262_at | SACS | spastic ataxia of Charlevoix-Saguenay (sacsin) 
223267_at | RG9MTD1 | RNA (guanine-9-) methyltransferase domain containing 1 
212202_s_at | TMEM87A | transmembrane protein 87A 
219553_at | NME7 | non-metastatic cells 7, protein expressed in (nucleoside-diphosphate 
kinase) 
202930_s_at | SUCLA2 | succinate-CoA ligase, ADP-forming, beta subunit 
202451_at | GTF2H1 | general transcription factor IIH, polypeptide 1, 62kDa 
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225200_at | DPH3 | DPH3, KTI11 homolog (S. cerevisiae) 
221923_s_at | NPM1 | nucleophosmin (nucleolar phosphoprotein B23, numatrin) 
226332_at | FAM133B | family with sequence similarity 133, member B 
201573_s_at | ETF1 | eukaryotic translation termination factor 1 
220553_s_at | PRPF39 | PRP39 pre-mRNA processing factor 39 homolog (S. cerevisiae) 
202467_s_at | COPS2 | COP9 constitutive photomorphogenic homolog subunit 2 
(Arabidopsis) 
224523_s_at | C3orf26 | chromosome 3 open reading frame 26 
229838_at | NUCB2 | nucleobindin 2 
228822_s_at | USP16 | ubiquitin specific peptidase 16 
225676_s_at | DCAF13 | DDB1 and CUL4 associated factor 13 
1557239_at | BBX | bobby sox homolog (Drosophila) 
226587_at | SNRPN | small nuclear ribonucleoprotein polypeptide N 
1552480_s_at | PTPRC | protein tyrosine phosphatase, receptor type, C 
201608_s_at | PWP1 | PWP1 homolog (S. cerevisiae) 
1555996_s_at | EIF4A2 | eukaryotic translation initiation factor 4A, isoform 2 
237466_s_at | HHIP | hedgehog interacting protein 
214683_s_at | CLK1 /// PPIL3 | CDC-like kinase 1 /// peptidylprolyl isomerase 
(cyclophilin)-like 3 
205280_at | GLRB | glycine receptor, beta 
212177_at | SFRS18 | splicing factor, arginine/serine-rich 18 
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233080_s_at | PRPF40A | PRP40 pre-mRNA processing factor 40 homolog A (S. 
cerevisiae) 
226671_at | LAMP2 | lysosomal-associated membrane protein 2 
1556283_s_at | FGFR1OP2 | FGFR1 oncogene partner 2 
226794_at | STXBP5 | syntaxin binding protein 5 (tomosyn) 
223263_s_at | FGFR1OP2 | FGFR1 oncogene partner 2 
214764_at | RRP15 | ribosomal RNA processing 15 homolog (S. cerevisiae) 
215719_x_at | FAS | Fas (TNF receptor superfamily, member 6) 
221107_at | CHRNA9 | cholinergic receptor, nicotinic, alpha 9 
208993_s_at | PPIG | peptidylprolyl isomerase G (cyclophilin G) 
222837_s_at | NARG1 | NMDA receptor regulated 1 
221193_s_at | ZCCHC10 | zinc finger, CCHC domain containing 10 
1553179_at | ADAMTS19 | ADAM metallopeptidase with thrombospondin type 1 motif, 
19 
201599_at | OAT | ornithine aminotransferase (gyrate atrophy) 
223087_at | ECHDC1 | enoyl Coenzyme A hydratase domain containing 1 
219158_s_at | NARG1 | NMDA receptor regulated 1 
221547_at | PRPF18 | PRP18 pre-mRNA processing factor 18 homolog (S. cerevisiae) 
201606_s_at | PWP1 | PWP1 homolog (S. cerevisiae) 
210117_at | SPAG1 | sperm associated antigen 1 
218349_s_at | ZWILCH | Zwilch, kinetochore associated, homolog (Drosophila) 
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203202_at | KRR1 | KRR1, small subunit (SSU) processome component, homolog 
(yeast) 
225180_at | TTC14 | tetratricopeptide repeat domain 14 
202950_at | CRYZ | crystallin, zeta (quinone reductase) 
230375_at | SFRS18 | splicing factor, arginine/serine-rich 18 
226459_at | PIK3AP1 | phosphoinositide-3-kinase adaptor protein 1 
212591_at | RBM34 | RNA binding motif protein 34 
206653_at | POLR3G | polymerase (RNA) III (DNA directed) polypeptide G (32kD) 
235610_at | ALKBH8 | alkB, alkylation repair homolog 8 (E. coli) 
225194_at | PLRG1 | pleiotropic regulator 1 (PRL1 homolog, Arabidopsis) 
212648_at | DHX29 | DEAH (Asp-Glu-Ala-His) box polypeptide 29 
220060_s_at | C12orf48 | chromosome 12 open reading frame 48 
203970_s_at | PEX3 | peroxisomal biogenesis factor 3 
1569136_at | MGAT4A | Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme A 
209475_at | USP15 | ubiquitin specific peptidase 15 
213704_at | RABGGTB | Rab geranylgeranyltransferase, beta subunit 
222500_at | PPIL1 | peptidylprolyl isomerase (cyclophilin)-like 1 
231784_s_at | DCAF13 | DDB1 and CUL4 associated factor 13 
227277_at | MTDH | metadherin 
232156_at | MUDENG | MU-2/AP1M2 domain containing, death-inducing 
213188_s_at | MINA | MYC induced nuclear antigen 
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219015_s_at | ALG13 | asparagine-linked glycosylation 13 homolog (S. cerevisiae) 
236620_at | RIF1 | RAP1 interacting factor homolog (yeast) 
1552344_s_at | CNOT7 | CCR4-NOT transcription complex, subunit 7 
203341_at | CEBPZ | CCAAT/enhancer binding protein (C/EBP), zeta 
202662_s_at | ITPR2 | inositol 1,4,5-triphosphate receptor, type 2 
216996_s_at | FASTKD2 | FAST kinase domains 2 
204807_at | TMEM5 | transmembrane protein 5 
200690_at | HSPA9 | heat shock 70kDa protein 9 (mortalin) 
218512_at | WDR12 | WD repeat domain 12 
201779_s_at | RNF13 | ring finger protein 13 
218750_at | TAF1D | TATA box binding protein (TBP)-associated factor, RNA 
polymerase I, D, 41kDa 
218967_s_at | PTER | phosphotriesterase related 
206034_at | SERPINB8 | serpin peptidase inhibitor, clade B (ovalbumin), member 8 
214943_s_at | RBM34 | RNA binding motif protein 34 
201745_at | TWF1 | twinfilin, actin-binding protein, homolog 1 (Drosophila) 
206158_s_at | CNBP | CCHC-type zinc finger, nucleic acid binding protein 
213483_at | PPWD1 | peptidylprolyl isomerase domain and WD repeat containing 1 
202660_at | ITPR2 | inositol 1,4,5-triphosphate receptor, type 2 
205530_at | ETFDH | electron-transferring-flavoprotein dehydrogenase 
201068_s_at | PSMC2 | proteasome (prosome, macropain) 26S subunit, ATPase, 2 
204285_s_at | PMAIP1 | phorbol-12-myristate-13-acetate-induced protein 1 
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238214_at | LRRC69 | leucine rich repeat containing 69 
227987_at | VPS13A | vacuolar protein sorting 13 homolog A (S. cerevisiae) 
233251_at | STRBP | Spermatid perinuclear RNA binding protein 
202939_at | ZMPSTE24 | zinc metallopeptidase (STE24 homolog, S. cerevisiae) 
201111_at | CSE1L | CSE1 chromosome segregation 1-like (yeast) 
1569484_s_at | MDN1 | MDN1, midasin homolog (yeast) 
209838_at | COPS2 | COP9 constitutive photomorphogenic homolog subunit 2 
(Arabidopsis) 
215165_x_at | UMPS | uridine monophosphate synthetase 
219802_at | PYROXD1 | pyridine nucleotide-disulphide oxidoreductase domain 1 
204840_s_at | EEA1 | early endosome antigen 1 
219002_at | FASTKD1 | FAST kinase domains 1 
202542_s_at | AIMP1 | aminoacyl tRNA synthetase complex-interacting multifunctional 
protein 1 
212896_at | SKIV2L2 | superkiller viralicidic activity 2-like 2 (S. cerevisiae) 
213189_at | MINA | MYC induced nuclear antigen 
202146_at | IFRD1 | interferon-related developmental regulator 1 
236696_at | SR140 | U2-associated SR140 protein 
221782_at | DNAJC10 | DnaJ (Hsp40) homolog, subfamily C, member 10 
205279_s_at | GLRB | glycine receptor, beta 
214130_s_at | PDE4DIP | phosphodiesterase 4D interacting protein 
235564_at | ZNF117 | Zinc finger protein 117 
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232630_at | APIP | APAF1 interacting protein 
233819_s_at | RNF160 | ring finger protein 160 
201144_s_at | EIF2S1 | eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa 
213878_at | PYROXD1 | pyridine nucleotide-disulphide oxidoreductase domain 1 
213424_at | KIAA0895 | KIAA0895 
226776_at | ENY2 | enhancer of yellow 2 homolog (Drosophila) 
204914_s_at | SOX11 | SRY (sex determining region Y)-box 11 
227777_at | C10orf18 | chromosome 10 open reading frame 18 
221514_at | UTP14A | UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) 
232238_at | ASPM | asp (abnormal spindle) homolog, microcephaly associated 
(Drosophila) 
226811_at | FAM46C | family with sequence similarity 46, member C 
239835_at | KBTBD8 | kelch repeat and BTB (POZ) domain containing 8 
221652_s_at | C12orf11 | chromosome 12 open reading frame 11 
203095_at | MTIF2 | mitochondrial translational initiation factor 2 
201083_s_at | BCLAF1 | BCL2-associated transcription factor 1 
200880_at | DNAJA1 | DnaJ (Hsp40) homolog, subfamily A, member 1 
221773_at | ELK3 | ELK3, ETS-domain protein (SRF accessory protein 2) 
212604_at | MRPS31 | mitochondrial ribosomal protein S31 
223707_at | RPL27A | ribosomal protein L27a 
231863_at | ING3 | inhibitor of growth family, member 3 
201873_s_at | ABCE1 | ATP-binding cassette, sub-family E (OABP), member 1 
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222684_s_at | NOL10 | nucleolar protein 10 
209095_at | DLD | dihydrolipoamide dehydrogenase 
212296_at | PSMD14 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 
1555125_at | C21orf66 | chromosome 21 open reading frame 66 
59644_at | BMP2K | BMP2 inducible kinase 
210346_s_at | CLK4 | CDC-like kinase 4 
212721_at | SFRS12 | splicing factor, arginine/serine-rich 12 
232291_at | MIR17HG | MIR17 host gene (non-protein coding) 
201210_at | DDX3X | DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 
209849_s_at | RAD51C | RAD51 homolog C (S. cerevisiae) 
212286_at | ANKRD12 | ankyrin repeat domain 12 
227447_at | SKIV2L2 | superkiller viralicidic activity 2-like 2 (S. cerevisiae) 
218462_at | BXDC5 | brix domain containing 5 
218403_at | TRIAP1 | TP53 regulated inhibitor of apoptosis 1 
209750_at | NR1D2 | nuclear receptor subfamily 1, group D, member 2 
210116_at | SH2D1A | SH2 domain protein 1A 
228395_at | GLT8D1 | Glycosyltransferase 8 domain containing 1 
220330_s_at | SAMSN1 | SAM domain, SH3 domain and nuclear localization signals 1 
222679_s_at | DCUN1D1 | DCN1, defective in cullin neddylation 1, domain containing 1 
(S. cerevisiae) 
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List of Down regulated genes arranged by decreasing intensity: 
 
Probe Set ID | Gene Symbol | Gene Title 
202912_at | ADM | adrenomedullin 
202718_at | IGFBP2 | insulin-like growth factor binding protein 2, 36kDa 
202887_s_at | DDIT4 | DNA-damage-inducible transcript 4 
227510_x_at | MALAT1 | metastasis associated lung adenocarcinoma transcript 1 (non-
protein coding) 
202022_at | ALDOC | aldolase C, fructose-bisphosphate 
228770_at | GPR146 | G protein-coupled receptor 146 
201170_s_at | BHLHE40 | basic helix-loop-helix family, member e40 
1553185_at | RASEF | RAS and EF-hand domain containing 
202856_s_at | SLC16A3 | solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
1553186_x_at | RASEF | RAS and EF-hand domain containing 
231721_at | JAM3 | junctional adhesion molecule 3 
210512_s_at | VEGFA | vascular endothelial growth factor A 
202855_s_at | SLC16A3 | solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
231720_s_at | JAM3 | junctional adhesion molecule 3 
242064_at | SDK2 | sidekick homolog 2 (chicken) 
211454_x_at | FKSG49 | FKSG49 
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228499_at | PFKFB4 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 
223199_at | MKNK2 | MAP kinase interacting serine/threonine kinase 2 
203828_s_at | IL32 | interleukin 32 
227744_s_at | HNRNPD | Heterogeneous nuclear ribonucleoprotein D (AU-rich element 
RNA binding protein 1, 37kDa) 
200872_at | S100A10 | S100 calcium binding protein A10 
213350_at | RPS11 | Ribosomal protein S11 
217137_x_at | LOC100291812 | hypothetical protein LOC100291812 
201848_s_at | BNIP3 | BCL2/adenovirus E1B 19kDa interacting protein 3 
206323_x_at | OPHN1 | oligophrenin 1 
201849_at | BNIP3 | BCL2/adenovirus E1B 19kDa interacting protein 3 
220232_at | SCD5 | stearoyl-CoA desaturase 5 
200632_s_at | NDRG1 | N-myc downstream regulated 1 
205199_at | CA9 | carbonic anhydrase IX 
225530_at | MOBKL2A | MOB1, Mps One Binder kinase activator-like 2A (yeast) 
224321_at | TMEFF2 | transmembrane protein with EGF-like and two follistatin-like 
domains 2 
208998_at | UCP2 | uncoupling protein 2 (mitochondrial, proton carrier) 
211791_s_at | KCNAB2 | potassium voltage-gated channel, shaker-related subfamily, 
beta member 2 
228204_at | PSMB4 | Proteasome (prosome, macropain) subunit, beta type, 4 
205349_at | GNA15 | guanine nucleotide binding protein (G protein), alpha 15 (Gq class) 
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224288_x_at | FKSG49 | FKSG49 
1556316_s_at | LOC284889 | hypothetical protein LOC284889 
219599_at | EIF4B | eukaryotic translation initiation factor 4B 
218205_s_at | MKNK2 | MAP kinase interacting serine/threonine kinase 2 
210045_at | IDH2 | isocitrate dehydrogenase 2 (NADP+), mitochondrial 
218625_at | NRN1 | neuritin 1 
217294_s_at | ENO1 | enolase 1, (alpha) 
211019_s_at | LSS | lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) 
212813_at | JAM3 | junctional adhesion molecule 3 
210132_at | EFNA3 | ephrin-A3 
201313_at | ENO2 | enolase 2 (gamma, neuronal) 
227799_at | MYO1G | myosin IG 
208120_x_at | FKSG49 /// tcag7.1056 | FKSG49 /// hypothetical LOC402469 
225762_x_at | LOC284801 | hypothetical protein LOC284801 
235163_at | MOBKL2A | MOB1, Mps One Binder kinase activator-like 2A (yeast) 
217202_s_at | GLUL | glutamate-ammonia ligase (glutamine synthetase) 
206792_x_at | PDE4C | phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 
dunce homolog, Drosophila) 
220796_x_at | SLC35E1 | solute carrier family 35, member E1 
203366_at | POLG | polymerase (DNA directed), gamma 
203282_at | GBE1 | glucan (1,4-alpha-), branching enzyme 1 
219622_at | RAB20 | RAB20, member RAS oncogene family 
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202028_s_at | RPL38 | ribosomal protein L38 
221943_x_at | RPL38 | Ribosomal protein L38 
200908_s_at | RPLP2 | ribosomal protein, large, P2 
224284_x_at | FKSG49 | FKSG49 
200648_s_at | GLUL | glutamate-ammonia ligase (glutamine synthetase) 
213826_s_at | LOC100133109 | hypothetical LOC100133109 
238701_x_at | C11orf92 | chromosome 11 open reading frame 92 
234981_x_at | CMBL | carboxymethylenebutenolidase homolog (Pseudomonas) 
208962_s_at | FADS1 | fatty acid desaturase 1 
234562_x_at | LOC728678 | Similar to p40 
234762_x_at | NLN | Neurolysin (metallopeptidase M3 family) 
217635_s_at | POLG | polymerase (DNA directed), gamma 
232266_x_at | CDC2L5 | Cell division cycle 2-like 5 (cholinesterase-related cell division 
controller) 
215978_x_at | LOC152719 | hypothetical protein LOC152719 
214715_x_at | ZNF160 | zinc finger protein 160 
203523_at | LSP1 | lymphocyte-specific protein 1 
211708_s_at | SCD | stearoyl-CoA desaturase (delta-9-desaturase) 
210240_s_at | CDKN2D | cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 
211934_x_at | GANAB | glucosidase, alpha; neutral AB 
218084_x_at | FXYD5 | FXYD domain containing ion transport regulator 5 
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212085_at | SLC25A6 | solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 6 
211911_x_at | HLA-B | major histocompatibility complex, class I, B 
211162_x_at | SCD | stearoyl-CoA desaturase (delta-9-desaturase) 
232215_x_at | PRR11 | proline rich 11 
211527_x_at | VEGFA | vascular endothelial growth factor A 
226549_at | SBK1 | SH3-binding domain kinase 1 
1554327_a_at | CANT1 | calcium activated nucleotidase 1 
208997_s_at | UCP2 | uncoupling protein 2 (mitochondrial, proton carrier) 
201367_s_at | ZFP36L2 | zinc finger protein 36, C3H type-like 2 
212044_s_at | RPL27A | Ribosomal protein L27a 
200751_s_at | HNRNPC | heterogeneous nuclear ribonucleoprotein C (C1/C2) 
201216_at | ERP29 | endoplasmic reticulum protein 29 
233571_x_at | PPDPF | pancreatic progenitor cell differentiation and proliferation factor 
homolog (zebrafish) 
226548_at | SBK1 | SH3-binding domain kinase 1 
237475_x_at | CCDC152 | coiled-coil domain containing 152 
217356_s_at | PGK1 | phosphoglycerate kinase 1 
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Genes affected in HIV ibfected cells treated with Dex/DEAE 
 
List of Upregulated genes arranged in decreasing intensity: 
Probe Set ID | Gene Symbol | Gene Title 
217238_s_at | ALDOB | aldolase B, fructose-bisphosphate 
218565_at | C9orf114 | chromosome 9 open reading frame 114 
225453_x_at | CCDC124 | Coiled-coil domain containing 124 
213736_at | COX5B | Cytochrome c oxidase subunit Vb 
210611_s_at | DTNA | dystrobrevin, alpha 
213087_s_at | EEF1D | eukaryotic translation elongation factor 1 delta (guanine 
nucleotide exchange protein) 
214395_x_at | EEF1D | eukaryotic translation elongation factor 1 delta (guanine 
nucleotide exchange protein) 
226014_at | EIF3F | Eukaryotic translation initiation factor 3, subunit F 
219599_at | EIF4B | eukaryotic translation initiation factor 4B 
234464_s_at | EME1 | essential meiotic endonuclease 1 homolog 1 (S. pombe) 
1555826_at | EPR1 | effector cell peptidase receptor 1 (non-protein coding) 
213621_s_at | GUK1 | Guanylate kinase 1 
227744_s_at | HNRNPD | Heterogeneous nuclear ribonucleoprotein D (AU-rich element 
RNA binding protein 1, 37kDa) 
213826_s_at | LOC100133109 | hypothetical LOC100133109 
213789_at | LOC100292959 | similar to hCG2042049 
112 
 
225934_at | LOC148413 | hypothetical LOC148413 
1556316_s_at | LOC284889 | hypothetical protein LOC284889 
221997_s_at | MRPL52 | Mitochondrial ribosomal protein L52 
222027_at | NUCKS1 | Nuclear casein kinase and cyclin-dependent kinase substrate 1 
202243_s_at | PSMB4 | proteasome (prosome, macropain) subunit, beta type, 4 
228204_at | PSMB4 | Proteasome (prosome, macropain) subunit, beta type, 4 
219138_at | RPL14 | ribosomal protein L14 
212044_s_at | RPL27A | Ribosomal protein L27a 
214041_x_at | RPL37A | Ribosomal protein L37a 
202028_s_at | RPL38 | ribosomal protein L38 
221943_x_at | RPL38 | Ribosomal protein L38 
200908_s_at | RPLP2 | ribosomal protein, large, P2 
213350_at | RPS11 | Ribosomal protein S11 
213665_at | SOX4 | SRY (sex determining region Y)-box 4 
227244_s_at | SSU72 | SSU72 RNA polymerase II CTD phosphatase homolog (S. 
cerevisiae) 
List of Down regulated genes arranged by decreasing intensity: 
Probe Set ID | Gene Symbol | Gene Title 
224496_s_at | TMEM107 | transmembrane protein 107 
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APPENDIX B 
SELECTIVE TOXICITY ASSAY 
Cell maintenance 
JURKAT cells (human T-lymphocytes; ATCC) were maintained in clear RPMI-1640 
without L- Glutamine and phenol red, prepared with 10% fetal bovine serum (FBS), 2 
mM L-glutamine, 1 mM Na Pyruvate. Cells were maintained at 37°C in a 5% CO2 
environment. 
Seeding the cells: 
100μL of media containing 300.104 cells/mL was plated in round-bottom 96-well plates 
(for a final concentration of 150.103 cells/well since each well is going to contain 200μL 
as follows: 100μL of cells in media and 100μL of drug dilutions in media with virus or 
PBS); leaving the outer rows to avoid the edge effect . And leave 2 rows for background 
reading with media only. 
Infecting the cells with HIV: 
A solution of media and DEAE-dextran (DD) was prepared to reach a final concentration 
of 40μg/mL in well. This solution was split in two; one with HIV virus added to it in 
order to attain 0.1 MOI in 96 well plate, while the other half had an equal volume of PBS 
added to it. 
80μL of this respective solutions were added into two 96 well plate, adding the HIV 
containing solution into one plate and the HIV negative solution into the other one  
The plates were incubated at 37°C in a 5% CO2 environment for 4 hours, to give the 
virus enough time to infect the cells. 
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Treating the cells: 
After 4hours of incubation, 20μL of a dilution of drugs were added into the plates: 
Dexamethasone (FAT080343) for a final concentration of 0.1μM, DEAE 
Diethylaminoethanol (FAT451505) for a final concentration of 6.9μM, Procaine 
(FAT031545) for a final concentration of 6.9μM, combination of DEAE/ 
Dexamethasone, a combination of procaine/ Dexamethasone. Each of the drugs is added 
in duplicate row, the final plate layout is as shown in the table bellow,  
Then the plates were placed on a shaking table, 150rpm for 5 minutes, to thoroughly mix 
the samples into the media, before being incubated at 37°C in a 5% CO2 environment for 
48 hours to allow the drug to take effect.
 
XTT Plate for Dex DEAE SelTox expt. infected on 08.10.24 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Control  Control  Control  Control  Control  Control  Control  Control  Control Control Control Control 
B Pre-inc 
2hr  No 
HIV 
Dex 
0.1uM 
Pre-inc 
2hr  No 
HIV 
Dex 
0.1uM 
Pre-inc 
2hr  No 
HIV 
Dex 
0.1uM 
Pre-inc 
2hr  No 
HIV 
Dex 
0.1uM 
Pre-inc 
2hr  HIV 
Dex 
0.1uM 
Pre-inc 
2hr  HIV 
Dex 
0.1uM 
Pre-inc 
2hr  HIV 
Dex 
0.1uM 
Pre-inc 
2hr  HIV 
Dex 
0.1uM 
Control Control Control Control 
C Pre-inc 
2hr  No 
HIV 
DEAE 
5uM 
Pre-inc 
2hr  No 
HIV 
DEAE 
5uM 
Pre-inc 
2hr  No 
HIV 
DEAE 
5uM 
Pre-inc 
2hr  No 
HIV 
DEAE 
5uM 
Pre-inc 
2hr  HIV 
DEAE 
5uM 
Pre-inc 
2hr  HIV 
DEAE 
5uM 
Pre-inc 
2hr  HIV 
DEAE 
5uM 
Pre-inc 
2hr  HIV 
DEAE 
5uM 
Control 
HIV+ 
Control 
HIV+ 
Control 
HIV+ 
Control 
HIV+ 
D Pre-inc 
2hr  No 
HIV 
COMBO 
Pre-inc 
2hr  No 
HIV 
COMBO 
Pre-inc 
2hr  No 
HIV 
COMBO
Pre-inc 
2hr  No 
HIV 
COMBO
Pre-inc 
2hr  HIV 
COMBO
Pre-inc 
2hr  HIV 
COMBO
Pre-inc 
2hr  HIV 
COMBO 
Pre-inc 
2hr  HIV 
COMBO
Control 
HIV+ 
Control 
HIV+ 
Control 
HIV+ 
Control 
HIV+ 
E Control  Control  Control  Control  Control  Control  Control 
HIV+ 
Control 
HIV+ 
Control 
HIV+ 
Control 
HIV+ 
Control 
HIV+ 
Control 
HIV+ 
F No HIV 
Dex 
0.1uM 
No HIV 
Dex 
0.1uM 
No HIV 
Dex 
0.1uM 
No HIV 
Dex 
0.1uM 
No HIV 
Dex 
0.1uM 
No HIV 
Dex 
0.1uM 
HIV+  
Dex 
0.1uM 
HIV+  
Dex 
0.1uM 
HIV+  
Dex 
0.1uM 
HIV+  
Dex 
0.1uM 
HIV+  
Dex 
0.1uM 
HIV+  
Dex 
0.1uM 
G No HIV 
DEAE 
5uM 
No HIV 
DEAE 
5uM 
No HIV 
DEAE 
5uM 
No HIV 
DEAE 
5uM 
No HIV 
DEAE 
5uM 
No HIV 
DEAE 
5uM 
HIV+ 
DEAE 
5uM 
HIV+ 
DEAE 
5uM 
HIV+ 
DEAE 
5uM 
HIV+ 
DEAE 
5uM 
HIV+ 
DEAE 
5uM 
HIV+ 
DEAE 
5uM 
H No HIV 
COMBO 
No HIV 
COMBO 
No HIV 
COMBO
No HIV 
COMBO
No HIV 
COMBO
No HIV 
COMBO
HIV+ 
COMBO 
HIV+ 
COMBO
HIV+ 
COMBO
HIV+ 
COMBO
HIV+ 
COMBO
HIV+ 
COMBO 
 1 2 3 4 5 6 7 8 9 10 11 12 
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Optimized protocol: 
Final vol in wells is 200uL; 100uL media already added in seeding, need another 100uL 
total volume (drug dilutions plus media +/- virus). 
DEAE-dextran (DD) stock is 100x, so for final volume of 200 uL per well, with 100 
wells (20 mL), use 200 uL DD stock added to 10mL media. 
44 of 96  wells have HIV; add HIV (32 uL stock) to 5.5 mL media + DD, no HIV to the 
other 6.5 mL   
Add 80 uL of respective media mixes to HIV+ or HIV- wells as required. 
Add either 20 uL of drug dilutions or 20 uL PBS to the appropriate wells
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
B Media 
buffer 
zone 
BLANK 
media 
only 
Control 
HIV+ 
HIV+ 
Dex 
0.1uM 
HIV+ 
DEAE 
5 uM 
HIV+ 
COMBO 
NO HIV 
COMBO 
NO 
HIV 
DEAE  
5 uM 
NO 
HIV  
Dex 
0.1uM 
Control   
NO 
HIV 
BLANK 
media 
only 
Media 
buffer 
zone 
C Media 
buffer 
zone 
BLANK 
media 
only 
Control  
HIV+ 
HIV+ 
Dex 
0.1uM 
HIV+ 
DEAE 
5 uM 
HIV+ 
COMBO 
NO HIV 
COMBO 
NO 
HIV 
DEAE  
5 uM 
NO 
HIV 
Dex 
0.1uM 
Control   
NO 
HIV 
 
BLANK 
media 
only 
Media 
buffer 
zone 
D Media 
buffer 
zone 
BLANK 
media 
only 
Control  
HIV+ 
HIV+ 
Dex 
0.1uM 
HIV+ 
DEAE 
5 uM 
HIV+ 
COMBO 
NO HIV 
 
COMBO 
NO 
HIV 
DEAE  
5 uM 
NO 
HIV 
Dex 
0.1uM 
Control   
NO 
HIV 
 
BLANK 
media 
only 
Media 
buffer 
zone 
E Media 
buffer 
zone 
BLANK 
media 
only 
Control  
HIV+ 
HIV+ 
Dex 
0.1uM 
HIV+ 
DEAE 
5 uM 
HIV+ 
COMBO 
NO HIV 
COMBO 
NO 
HIV 
DEAE  
5 uM 
NO 
HIV 
Dex 
0.1uM 
Control   
NO 
HIV 
 
BLANK 
media 
only 
Media 
buffer 
zone 
F Media 
buffer 
zone 
BLANK 
media 
only 
Control  
HIV+ 
HIV+ 
Dex 
0.1uM 
HIV+ 
DEAE 
5 uM 
HIV+ 
COMBO 
NO HIV 
COMBO 
NO 
HIV 
 
DEAE  
5 uM 
NO 
HIV 
Dex 
0.1uM 
Control   
NO 
HIV 
 
BLANK 
media 
only 
Media 
buffer 
zone 
G Media 
buffer 
zone 
BLANK 
media 
only 
Control  
HIV+ 
HIV+ 
Dex 
0.1uM 
HIV+ 
DEAE 
5 uM 
HIV+ 
COMBO 
NO HIV 
COMBO 
NO 
HIV 
DEAE  
5 uM 
NO 
HIV 
Dex 
0.1uM 
Control   
NO 
HIV 
 
BLANK 
media 
only 
Media 
buffer 
zone 
H Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
Media 
buffer 
zone 
 1 2 3 4 5 6 7 8 9 10 11 12 
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Live Dead assay Protocol: 
 
Control 
(HIV-) 
Control(HIV+) Dex DEAE Combo(HIV+) Combo(HIV-
) 
1mL (non 
infected 
Cells) 
+ 1mL 
RPMI 
1mL (infected 
Cells) 
+ 1mL RPMI 
1mL 
(infected 
Cells) 
+ 0.5mL 
RPMI 
+0.5 mL 
Dex 
1mL 
(infected 
Cells) 
+ 0.5mL 
RPMI 
+0.5mL 
DEAE 
1mL (infected 
Cells) 
+ 0.5mL Dex 
+0.5mL 
DEAE 
1mL (non 
infected 
Cells) 
+ 0.5mL Dex 
+0.5mL 
DEAE 
1mL (non 
infected 
Cells) 
+ 1mL 
RPMI 
1mL (infected 
Cells) 
+ 1mL RPMI 
1mL 
(infected 
Cells) 
+ 0.5mL 
RPMI 
+0.5 mL 
Dex 
1mL 
(infected 
Cells) 
+ 0.5mL 
RPMI 
+0.5mL 
DEAE 
1mL (infected 
Cells) 
+ 0.5mL Dex 
+0.5mL 
DEAE 
1mL (non 
infected 
Cells) 
+ 0.5mL Dex 
+0.5mL 
DEAE 
1mL (non 
infected 
Cells) 
+ 1mL 
RPMI 
1mL (infected 
Cells) 
+ 1mL RPMI 
1mL 
(infected 
Cells) 
+ 0.5mL 
RPMI 
+0.5 mL 
Dex 
1mL 
(infected 
Cells) 
+ 0.5mL 
RPMI 
+0.5mL 
DEAE 
1mL (infected 
Cells) 
+ 0.5mL Dex 
+0.5mL 
DEAE 
1mL (non 
infected 
Cells) 
+ 0.5mL Dex 
+0.5mL 
DEAE 
 
 
We need a final concentration in the wells of: 
0.1 uM Dex (4mg/mL) (F.W=516.4) 
6.9 uM DEAE (F.W= 117.19) 
So for a final volume of 2mL per well, we need to make a solution 4* as concentrated: 
0.4 uM of Dex in a total volume of 10mL RPMI 
27.6 uM of DEAE in a total volume of 10mL RPMI 
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Determining the optimal dye concentration: 
1. take 100uL per well of uninfected cells in a 96 well plates  
2. kill half the number of wells by:  
3. teat with increasing concentration of blue Calcein: 
0.1/0.25/0.5/0.75/1/2.5/5/7.5/10 
a. EthD-1: 0.1/0.25/0.5/0.75/1/2.5/5/7.5/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 0.1 0.25 0.5 0.75 1 2.5 5 7.5 10 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
calcein 
CEM-
GFP+ 
EthD-1 
CEM-
GFP+ 
EthD-1 
CEM-
GFP+ 
EthD-1 
CEM-
GFP+ 
EthD-1 
CEM-
GFP+ 
EthD-1 
CEM-
GFP+ 
EthD-
1 
CEM-
GFP+ 
EthD-1 
CEM-
GFP+ 
EthD-
1 
CEM-
GFP+ 
EthD-1 
CEM-
GFP+ 
EthD-1 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
calcein 
Rev-
CEM+ 
EthD-1 
Rev-
CEM+ 
EthD-1 
Rev-
CEM+ 
EthD-1 
Rev-
CEM+ 
EthD-1 
Rev-
CEM+ 
EthD-1 
Rev-
CEM+ 
EthD-
1 
Rev-
CEM+ 
EthD-1 
Rev-
CEM+ 
EthD-
1 
Rev-
CEM+ 
EthD-1 
Rev-
CEM+ 
EthD-1 
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Cell Media Preparation 
To make 500 mL of RPMI1640 Medium for CEM-GFP 
 
Starting with RPMI 1640, 1X Medium  
w/o L- Gln,  
 
RPMI1640     435mL  
10% FBS(fetal Bovine Serum)  50 mL  
1% of 200 mM L-Glutamine   5 mL of 200 mM solution  
1% Penicillin-streptomycin   5mL of Pen Strep Penicillin Streptomycin 
500 ug/mL of G-418    5 mL of 50mg/mL solution 
   
      
1. Remove a 50 mL aliquot of FBS from the freezer and thaw in warm water.  
 
2. Open a 500 mL bottle of fresh RPMI under sterile conditions 
 
3. Remove 65 mL of media.  
 
4. Add 5 mL of 200 mM L-glutamine from the -20 freezer  
 
5. Add 50 mL (56.8 mL) of FBS 
 
6. Add 5mL of Pen Strep Penicillin Streptomycin 
 
7. 5 mL of 50mg/mL of G-418solution 
 
8. Mix well, label bottle with initials, date, contents, etc. 
 
9. The media need not be filtered unless any of the reagents are not sterile 
(everything we purchase is cell culture grade) 
 
10. Place 1 mL of newly prepared media in the incubator overnight to check sterility 
before storing cell, if it turns cloudy there are bacteria partying in the medium. 
 
11. Media will last about 2 months in the refrigerator. 
 
 
 
121 
 
Procedure for Counting Cells 
Supplies needed: 
1 mL pipette 
2 sterile bullet tubes (smaller ones (500 µL are preferred) 
Sample from cell generation (60 - 100 µL) 
Trypan Blue (TB) (40 µL)  
Hematocytometer (slide with gridlines) 
Slide cover 
 
Procedure: 
 
1. Percuss the cells vigorously to dissociate the cells from each other. 
  
2. Open the cell flask and remove less than 100 µL of the media (fill the tip only). 
 
3. Place the sample in the bullet tube (if more than one flasks of cells is being 
counted be sure to label the bullet tubes). 
 
4. Place 40 µL of TB in the other bullet tube. 
 
5. To save plastic, reuse the pipette tip that was just used for the TB and remove 40 
µL of cells/media from the first bullet tube, being sure to mix the TB and the cells 
well in the bullet tube. (there is now a dilution factor of 2) 
 
6. Take the mixture in the bullet tube to the microscope. 
 
7. Place a cover slip over the slide and insert 20 µL of the cell media/TB mixture in 
the small groove in-between the cover slip and the slide. 
 
8. Place slide on the microscope and bring into focus the grid and cells. 
 
9. Bring into focus the gridlines, use the 0.25 magnification which will narrow the 
sight to one field. Count a total of 4 different fields. 
 
10. Counting cells: 
 
A method is needed so that there is consistency to the count. If cells placement is on 
top of a gridline count only cells on right and upper gridline and ignore cells on 
bottom and left gridline or vise versa. Either way, be consistent.  
 
Additionally, always move the slide in the same direction either clockwise or counter 
clockwise to count cells. Again, either way, be consistent.  
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If there is difficult focusing in on the gridline start with the lowest magnification 
(0.10) and graduate up in magnification power. 0.25 seems to work best. At this 
power one can see one field (4x4 squares) fully, making counting easy. 
 
The number between squares would be within 5% if the cells are evenly distributed. 
  
Keep an eye out for dead cells (dark blue) if there are numerous dead cells it is time 
to start troubleshooting. 
 
 
11. Using the counter, count number of cells in each 4x4 grid being sure to count all 
four of the 4x4 fields. 
 
12. Take the total number of cells counted and calculate the total number of cells:            
  (# of cells counted/4) x 2 x 104 c/mL) 
 
 
 
 
Cell senescence is characterized by changes in morphology and decreased growth 
rate. 
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Freezing Cells 
 
1. Spilt cells into a T-75 in 15 mL of media and grow until cell count is 8 x 105 or 9 x 105.   
 
2. Prepare media with 10% DMSO +  90% FBS. 
 
3. Calculate the number of cryovials (externally threaded) that will be needed to freeze 
cells.  Each cryovial should hold 2 x 106 cells  
CALCULATION:  (vol. media in T-75) x cell count (cells/mL) = # cells 
   # cells/2 x 106 = # vials needed 
 
4. Cryovials should be sterile and endotoxin free or autoclaved with drying to destroy 
endotoxin. 
 
5. Prepare the appropriate amount of STERILE freezing medium to have 1 mL per cryovial.  
The freezing medium is 7.5% DMSO in complete RPMI (with FBS) or the alternative 
mentioned above.   
CALCULATION:  # tubes x 1mL/tube = mL of media needed. 
 
6. Keep media at 4° C (on ice) during procedure.  
 
7. Fill cryocontainer with 100% isopropanol and be sure it is already cooled. 
 
8. While medium is warming, label the cryotubes with the cell type, generation, cell 
number, date, your initials.  Place clear tape over the labels to be sure that they don’t get 
washed off in the liquid N2. 
 
9. Be sure all supplies are ready and that all labeled tubes are under hood with caps off and 
ready to have cells added to them before putting cells in freezing medium (this is 
necessary because DMSO is toxic to cells and should only be combined with cells for the 
minimum amount of time). 
 
10. Spin cells in Falcon tube at 1500 rpm for 5 min. (check to be sure pellet has formed) 
 
11. Discard supernatant from cells and add the appropriate volume of freezing medium 
(calculated in step 5) 
 
12. Pipet gently up and down to resuspend cells. 
 
13. Aliquot 1 mL of cell mixture into each cryotube, replace lids. 
 
14. Place in -20° C for 2 hours. 
 
15. Move the vials to -80° C freezer and allow them to cool overnight. 
 
16. Move cells from cryostorage device to liquid nitrogen  in 4 -5 hr (although cells can 
survive up to 5 weeks at -80° C, better results are had with a shorter time). 
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Thawing Cells, protocol for bringing up cells from liquid N2 
 
Note: Vials that have been stored in liquid N2 can explode on warming if the vials are leaky. For this 
reason it is wise to where face protection and gloves. 
Be sure to test media for bacterial contamination by placing 5 mL in incubator for 24 hr. 
 
Supplies:  
1, 15 mL Falcon Tubes; 1 T-25 Flask; 10 mL media, 40 mL beaker of EtOH. 
 
1. Turn on water batch to 37˚ C.  
 
2. Prepare 1 T25 flask  and 1, 15 mL falcon tube with 5 mL media each. 
 
3. Remove cell vial from liquid N2.  Check that cap is securely fastened. Transfer 
immediately to 37˚ C water bath.  
 
4. Swirl gently (bottom half only) in bath until barely thawed (like sherbert). Be sure you 
have recovered any information recorded on the vial. 
 
5. Submerge vial in beaker of ETOH before placing vial under hood (water bath is a major 
source of contamination). Be sure the cap is on tight. Change your gloves. 
 
6. Under sterile hood, suck cells up in 1 mL pipette and transfer to falcon tube with 5 mL 
media already present.  Rinse pipette up and down to facilitate complete transfer. 
 
7. OR: Transfer cells immediately into 15 mL of media in T-25 flask place in incubator fro 
24 hr and then go to step 8.   
 
8. Spin @1500 rpm (no more than 800 rcf) for 5 min, should see pellet of cells (if media is 
cloudy, spin longer). 
 
9. Remove media-discard. 
 
10. Add < 5 mL of media, gently rinse up and down in pipette to resuspend pellet. {If the 
cells have been frozen for a long period of time (decreased cell viability) best to suspend 
the cells in a smaller volume of media. You can always add more media in 24 – 48 hr} 
11. Gently transfer into a T-25 falcon flask  
 
12. Label the flask with the date, the cell type, and your initials. 
 
13. Place in CO2 incubator at 39.6 ºC, 4.7% CO2, 72% relative humidity. 
 
14. Turn off water bath. 
 
15. Check cell count every 24 – 48 hours 
 
16. After 20 passages, cells should be discarded.  Old cells should be removed from the 
incubator. 
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General Cell Culture Procedures 
 
Helpful hints:  
 
1. Run UV light for 30 minutes before working under the sterile hood. 
2. Make sure all reagents, instruments etc are available before starting -- running 
back and forth between the cell culture room and a lab may introduce 
contamination. 
3. Keep cell culture room door closed at all times. 
4. Rule of thumb: Warm cells fast to wake, cool cells slow to store 
5. Experiments should be done on 1st or 2nd generation cells, never the original stock 
6. Incubator will need the sterile H2O changed every 2-3 mo.  Check incubator to 
make sure there is water present and add more if it is dry.   
 
General Comments about Cell Health: 
1. If media becomes lighter, pH has changed (more acidic) – change media 
2. If cells are detached from the flask, bad sign.  Check media, CO2 concentration, 
humidity, temperature, etc. 
3. 80 – 90% confluence is best for running an experiment, if confluence approaches 
100% cells will not be able to grow. 
4. Jurkats grow in clumps (T cells like to hang out together) 
5. Shape of cells: 
  Round   low growth 
  Fractal shape  active growth 
“giant” cells old cells (change media) (happens with cancer cells 
only) 
Cell Culture Lab Procedures 
 
Helpful hints:  
1. Make sure all reagents, instruments etc are available before starting, running back and  
forth between the cell culture room and a lab is a sure way to introduce contamination. 
2. Keep cell culture room door closed at all times while working under the hood. 
3. Always filter FBS to assure sterility. 
 Day before starting a culture, take 10 mLs of FBS and place in incubator, this will 
 demonstrate if there is bacterial contamination in the FBS within 24 h. 
 If the color of the media changes, change the media! 
4. when waking cells, cell growth is best in large populations, do not separate them. 
5. Media will last about 2 months in the refrigerator. 
6. Rule of thumb: Warm cells fast to wake, cool cells slow to store. 
7. DMSO 7% (or other specification depending on cells) should be used to put cells to 
bed (cyrostorage). 
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8. Experiments should be done on 1st or 2nd generation cells, never the original stock. 
9. 80-90% confluence is best for running an experiment, if confluence is at 100% cells 
will not be able to grow. 
10. Incubator will need sterile H2O every 2-3 mo. 
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Cell culture protocol for JC53 
 
To detach the cells from the plate we use EDTA without trypsin for JC53 because trypsin 
removes CD4 
- Remove medium from culture vessel by aspiration and wash the monolayer to 
remove all traces of serum.  
- add 10mL of (EDTA+PBS) enough to cover all the surface (EDTA takes longer 
time than trypsin) 
- Place culture in the 37°C incubator for 5 minutes. 
- Monitor cells under microscope. Cells are beginning to detach when they appear 
rounded. 
- As soon as cells are in suspension remove EDTA PBS, immediately add culture 
5mL of medium containing serum. Wash cells very well with serum containing 
medium ( to resuspend the cells)  
- transfer to a sterile centrifuge tube 
 
Viable cell counts. USING A HEMOCYTOMETER TO DETERMINE TOTAL CELL 
COUNTS AND VIABLE CELL NUMBERS 
 
(Trypan blue is used in dye exclusion procedures for viable cell counting. This method is 
based on the principle that live cells do not take up certain dyes, whereas dead cells do.)     
- combine 20 μl of cells with 20 μl of trypan blue suspension (about20Mix 
thoroughly and allow to stand for 5-15 minutes. 
- With the cover slip in place, transfer a small amount of trypan blue-cell 
suspension(about 20 μl) to both chambers of the hemocytometer by carefully 
touching the edge of the cover slip with the pipette tip and allowing each chamber 
to fill by capillary action. Do not overfill or underfill the chambers. 
-  Starting with 1 chamber of the hemocytometer, count all the cells in the 1 mm 
center square and four 1 mm corner square.  Keep a separate count of viable and 
non-viable cells. 
- The circle indicates the approximate area covered at 100X microscope 
magnification (10X ocular and 10X objective). Include cells on top and left 
touching middle line. Do not count cells touching middle line at bottom and right. 
Count 4 corner squares and middle square in both chambers and calculate the 
average. 
- Each large square of the hemocytometer, with cover-slip in place, represents a 
total volume of 0.1 mm3 or 10-4 cm3. Since 1 cm3 is equivalent to approximately 1 
ml, the total number of cells per ml will be determined using the following 
calculations: Cells/ml = average cell count per square x dilution factor x 104; 
Total cells = cells/ml x the original volume of fluid from which the cell sample was 
removed; % Cell viability = total viable cells (unstained)/total cells x 100. 
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- For a 96 well plate you put a low enough number of cells to grow depending on 
the incubation time (10-20.103 cells per well) you make your dilution depending 
on how many cells you want in your medium and then you distribute them in the 
wells (by multipipetting). 
- It take the cells 2hours to attach if they don’t in 2h it means they are not in good 
condition ( add the compounds active antiviral) 
- We incubate them overnight and infect them with HIV Virus. 
 
Infecting plated cells with HIV: 
 
- Set absorbent pad bellow work area 
- Use DEAE dextran to enhance Virus entry into cells (stock solution is 4 μg/μl , 
targe concentration =40μg/mL in wells) 
- Vial of virus stock(spray off with 70%ethanol) 
-1μL =0.1 MOI in 96 well palte 
-1μL = 10,000 Virus particles 
use 20μL virus to give 200,000 per plate, which is 20,000 per well (while 
we have 16,000 cells per well) 
  
- Fisrt mix the virus with 100μL/well of media per well 
 -10 mL media+9almost 10mL already on plate from seeding) 
 -20μL DEAE stock 
 -20μL virus stock 
- Mix in 15mL tube , add to pipette reservoir, then pipette bleach into empty 15mL 
tube to kill residual virus 
- Add 100μL virus/DEAE/media to each well using mltichannel pipette  
- (Don’t forget to not add virus to the rows that are background and uninfected 
controls, instead add 100μL of media alone (no virus) to these wells. 
- Change pipette tips after each rows to avoid cross contamination with drug in 
different wells. 
- Dump used pipette tips directly into beaker of bleach, rinse reservoir with bleach 
after use, dispose it in biohazard waste after replacing in original wrapper. 
 
Titer the viron 
 
You spin the infected cells with viron for 5min at 7,000 r.p.m 
- you get 500μL of the supernatant that contain the virus, add 10μL of DEAE 
(20/40μg/mL) to it. 
- add 100μL of the mixture(virus+DEAE) to the wells where you already have 
100μL of the media +cells 
- incubate the plate for 72hours  
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Luciferase assay: 
 
Use RPMI 16-40media with the luciferase buffer (which has lysis buffer to break 
down the cells, and substrate of luciferase enzyme ) 
 
We start by removing the media from the cells  
In the machine (polar star Optima) we pump the media first from the hose to the 
pump in order to avoid the dead volume. 
- you run the system washing the pumps. 
- we inject 100 μL of the buffer  +100 μL of the media, and measure luminescence , 
the plate in the computer is named NUNC96 and Layout is all of them. 
- The first reading is not good so you allow 5min and then you redo the reading in 
order to get more accurate results. 
- Then when you are done you wash the system afterwards with DI water. 
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Vybrant® MTT Cell Proliferation Assay Kit (V-13154) Protocol from Invitrogen 
[50] 
 
Reagent Preparation: 
 
1.1 Prepare a 12 mM MTT stock solution by adding 1 mL of sterile PBS to one 5 mg vial 
of MTT (Component A). Mix by vortexing or sonication until dissolved. 
Occasionally there may be some particulate material that will not dissolve; this can 
be removed by filtration or centrifugation. Each 5 mg vial of MTT provides 
sufficient reagent for 100 tests, using 10 µL of the stock solution per well. Once 
prepared, the MTT solution can be stored for four weeks at 4°C protected from light. 
1.2 Add 10 mL of 0.01 M HCl to one tube containing 1 gm of SDS (Component B). Mix 
the solution gently by inversion or sonication until the SDS dissolves. Once prepared, 
the solution should be used promptly. Each tube makes sufficient solution for 100 
tests, using 100 µL per well. 
 
Quantitation of Jurkat cells using the Vybrant MTT Cell Proliferation Assay Kit: 
 
Cells in the parent culture were counted in a hemacytometer and then diluted to the 
indicated cell numbers in 100 µL volumes, delivered to the wells of a microplate and 
incubated for 4 hours to allow time for adsorption before being assayed. Absorbance 
measurements at 570 nm were made using a microplate reader. Each data point represents 
the mean value of samples in triplicate. The inset shows the data plotted for the lower cell 
numbers. 2 Vybrant® MTT Cell Proliferation Assay Kit data. The age of the cultures, 
number of passages and details of the growth medium can all be important factors. 
Natural variation in the requirements and growth rates of different cell lines make it 
difficult to provide precise guidelines for preparing your cells. 
In general, cells seeded at densities between 5000 to 10,000 cells per well should reach 
optimal population densities within 48 to72 hours. Note that the presence of phenol red in 
the final assay samples can seriously affect results. We strongly recommend that the cells 
be cultured in medium free of phenol red, if possible. Alternatively, the final incubation 
with the MTT can be performed after exchanging the cells into medium free of phenol 
red. 
 
Labeling Cells:   
 
2.1  For adherent cells, remove the medium and replace it with 100 µL of fresh culture 
medium. For non-adherent cells, centrifuge the microplate, pellet the cells, carefully 
remove as much medium as possible and replace it with 100 µL of fresh medium. 
2.2 Add 10 µL of the 12 mM MTT stock solution (prepared in step 1.1) to each well. 
Include a negative control of 10 µL of the MTT stock solution added to 100 µL of 
medium alone. 
2.3  Incubate at 37°C for 4 hours. At high cell densities (>100,000 cells per well) the 
incubation time can be shortened to 2 hours. 
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2.4 Add 100 µL of the SDS-HCl solution (prepared in step 1.2) to each well and mix 
thoroughly using the pipette. 
2.5  Incubate the microplate at 37°C for 4–18 hours in a humidified chamber. Longer 
incubations will decrease the sensitivity of the assay. 
2.6 Mix each sample again using a pipette and read absorbance at 570 nm. 
 
Quick Protocol Option: 
 
To shorten the time of the assay it is possible to use DMSO (not provided) as a 
solubilizing agent to dissolve the formazan.6 
3.1 After labeling the cells with MTT, as described above, remove all but 25 µL of 
medium from the wells. For non-adherent cells it may be necessary to first 
centrifuge the plates to sediment the cells. 
3.2 Add 50 µL of DMSO to each well and mix thoroughly with the pipette. 
3.3 Incubate at 37°C for 10 minutes. 
3.4 Mix each sample again and read absorbance at 540 nm  not 570 nm, as above. 
 
 
 
